 
A RANDOMIZED, DOUBLE- BLIND, PLACEBO -CONTROLLED, FIXED SEQUENCE 
STUDY TO ASSESS THE EFFECT ON RESPIRATORY DRIVE OF MULTIPLE 
DOSES OF AZD4041 WHEN CO -ADMINISTERED WITH A SINGLE DOSE OF 
MORPHINE IN HEALTHY RECREATIONAL OPIOID USERS  
Protocol Number:  D7460C00003  
Altasciences Project Number:  AZN -P1-265 
Investigational Product:  AZD4041  
Phase of Development:  Phase 1 
Sponsor:  AstraZeneca  AB 
151 85 Södertälje 
Sweden  
COMPLIANCE  
The study will be conducted in accordance with standards of Good Clinical Practice, as defined by the 
International Council for  Harmonisation and all applicable federal and local regulations . 
Protocol Version  Date  
1.0 (Original)  August 09, 2022  
2.0 (Amendment 01)  September 16, 2022  
 
  CONFIDENTIALITY STATEMENT  
The information provided in this document is strictly confidential and is available for review to investigator(s) 
and to the  appropriate Independent Ethics Committee  (IEC) or Institutional Review Board (IRB). It may not be 
used, divulged, published or otherwise disclos ed without the written authoriza tion from Altasciences  or the 
sponsor.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 2 of 95 PROTOCOL AMENDMENT 01 – SUMMARY OF CHANGES  
Description of Change Made Section/Location  Rationale 
Changed manufacturer, 
concentration and volume of administration of opioid treatment (morphine).  • Study Synopsis (Opioid, Dose, and Mode of Administration) 
• Section 3.2 (Study Treatments) 
• Section 5.1.2 (Morphine) Lack of supply by original manufacturer.  
Clarified a discrepancy in exclusion criterion #23.  Changed: 
‘Positive test result for 
alcohol and/or drugs of abuse upon admission on Day -1.’ 
To: 
‘Positive test result for 
alcohol and/or drugs of abuse upon admission on Day -2.’ Section 4.2 (Exclusion Criteria) To be consistent with the accurate information presented in Table 6 -1 
(Schedule of Activities)  
 
  
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 3 of 95 TABLE OF CONTENTS 
PROTOCOL AMENDMENT 01 – SUMMARY OF CHANGES ........................................................................... 2  
TABLE OF CONTENTS ............................................................................................................. ............................... 3  
LIST OF IN-TEXT TABLES ........................................................................................................ ............................. 7  
LIST OF IN-TEXT FIGURES ....................................................................................................... ............................ 8  
STUDY SYNOPSIS ................................................................................................................ ..................................... 9  
STUDY ADMINISTRATIVE STRUCTURE ................................................................................................ ......... 14  
1. INTRODUCTION .................................................................................................................. ............................ 15  
1.1. Background .................................................................................................................... ............................... 15  
1.2. Study Rationale ............................................................................................................... .............................. 16  
1.3. Risk/Benefit Assessment ....................................................................................................... ........................ 16  
1.3.1.  Known Potential Benefits....................................................................................................... ................ 16  
1.3.2.  Important Potential Risks ..................................................................................................... .................. 17  
1.3.3.  Risk/Benefit Conclusion ....................................................................................................... ................. 23  
2. STUDY OBJECTIVES AND ENDPOINTS ................................................................................................ .... 25  
3. STUDY DESIGN .................................................................................................................. .............................. 26  
3.1. Overall Study Desi gn .......................................................................................................... .......................... 26  
3.2. Study Treatments .............................................................................................................. ............................. 28  
4. SUBJECT POPULATION ............................................................................................................ .................... 28  
4.1. Inclusion Criteria ............................................................................................................ ............................... 28  
4.2. Exclusion Criteria ............................................................................................................ .............................. 29  
4.3. Rescreening Criteria .......................................................................................................... ............................ 32  
4.4. Withdrawal Criteria ........................................................................................................... ............................ 32  
4.4.1.  Before First Treatment Ad ministration ......................................................................................... ......... 32  
4.4.2.  After First Treatment Ad ministration .......................................................................................... ........... 32  
4.5. Lifestyle and/or Dietar y Requirements.......................................................................................... ................ 34  
4.6. Concomitant Treatment ......................................................................................................... ........................ 35  
5. STUDY TREATMENTS .............................................................................................................. ...................... 35  
5.1. Investigational Prod ucts ...................................................................................................... .......................... 35  
5.1.1.  AZD4041  and Placebo oral solution ................................................................................... 35  
5.1.2.  Morphine ...................................................................................................................... .......................... 36  
5.2. Investigational Product Management ............................................................................................ ................ 36  
5.2.1.  Packaging, Labeling an d Dispensing ............................................................................................ ......... 36  
5.2.2.  Storage and Handling .......................................................................................................... ................... 36  
5.2.3.  Method of Assigning Subjects to  Treatment Groups ............................................................................. 36 
5.2.4.  Blinding ...................................................................................................................... ............................ 37  CCI
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 4 of 95 5.2.5.  Study Drug Accountability  .....................................................................................................................  37 
5.3. Administration of Study Drug .......................................................................................................................  37 
5.4. Meals  .............................................................................................................................................................  38 
5.5. Fluids  .............................................................................................................................................................  38 
5.6. Other Protocol Restrictions  ...........................................................................................................................  38 
6. STUDY PROCEDURES  ....................................................................................................................................  38 
6.1. Safety Assessments  .......................................................................................................................................  44 
6.1.1.  Medical History  ......................................................................................................................................  44 
6.1.2.  Recreational Alcohol/Drug Use  .............................................................................................................  44 
6.1.3.  Physical Examination  .............................................................................................................................  44 
6.1.4.  Neurological Examination  ......................................................................................................................  44 
6.1.5.  Vital Signs  .............................................................................................................................................. 44 
6.1.6.  12-Lead Electrocardiogram  ....................................................................................................................  45 
6.1.7.  ECG Telemetry  ......................................................................................................................................  52 
6.1.8.  Continuous and Spot Oxygen Saturation  ...............................................................................................  53 
6.1.9.  Continuous and Spot End -Tidal Carbon Dioxide  ...................................................................................  53 
6.1.10.  Continuous and Spot Respiratory Rate ..................................................................................................  54 
6.1.11.  Laboratory Evaluations  ..........................................................................................................................  55 
6.1.12.  Columbia Suicide Severity Rating Scale (C- SSRS)  ...............................................................................  55 
6.1.13.  Clinical Opioid Withdrawal Scale (COWS)  ...........................................................................................  56 
6.1.14.  Assessment of Respiratory Depression  ..................................................................................................  56 
6.1.15.  Medical Interventions for Signs of Respiratory Depress ion...................................................................  56 
6.1.16.  Rescue Therapy  ......................................................................................................................................  57 
6.2. Pharmacokinetic Assessments  .......................................................................................................................  57 
6.2.1.  Pharmacokinetic Blood Sampling  ..........................................................................................................  57 
6.2.2.  Pharmacokinetic Urine Sampling  ...........................................................................................................  59 
6.2.3.  Pharmacokinetic Sample Processing, Storage and Shipping  ..................................................................  59 
7. ADVERSE EVENTS DOCUMENTATION  ....................................................................................................  59 
7.1. Definitions  .....................................................................................................................................................  59 
7.2. Severit y Assessment  ......................................................................................................................................  60 
7.3. Causality Assessment  ....................................................................................................................................  61 
7.4. Adverse Event Monitoring  ............................................................................................................................  61 
7.5. Reporting of Pregnancy ................................................................................................................................. 62 
7.6. Serious Adverse Event Reporting  .................................................................................................................  62 
8. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS  ...................................................................  63 
8.1. Analysis Populations  .....................................................................................................................................  63 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 5 of 95 8.1.1.  Randomized Population  .........................................................................................................................  63 
8.1.2.  Safety Population  ...................................................................................................................................  63 
8.1.3.  Completer Population  .............................................................................................................................  64 
8.1.4.  Pharmacokinetic Population  ...................................................................................................................  64 
8.2. Demographic Data and Other Baseline Characteristics  .................................................................................  64 
8.3. Safety.............................................................................................................................................................  64 
8.3.1.  Safety Endpoints  ....................................................................................................................................  64 
8.3.2.  Safety Analysis  ......................................................................................................................................  65 
8.4. Pharmacokinetics  ..........................................................................................................................................  68 
8.4.1.  Pharmacokinetic Parameters  ..................................................................................................................  68 
8.4.2.  Summary and Presentation of PK data  ...................................................................................................  70 
8.4.3.  Pharmacokinetic Statistical Methodology  .............................................................................................. 70 
8.5. Determination of Sample Size  .......................................................................................................................  70 
9. REFERENCES  ...................................................................................................................................................  71 
10. APPENDIX 1: ETHICS  .....................................................................................................................................  77 
10.1.  Institutional Review Board  ............................................................................................................................  77 
10.2.  Ethical Conduct of the Study  .........................................................................................................................  77 
10.3.  Subject Information and Consent  ..................................................................................................................  77 
10.4.  Subject Confidentiality  ..................................................................................................................................  77 
11. APPENDIX 2: DATA COLLECTION, RETENTION, AND MONITORING  ............................................ 78 
11.1.  Case Report Forms  ........................................................................................................................................  78 
11.2.  Data Management and Processing  .................................................................................................................  78 
11.3.  Quality Control and Quality Assurance  ........................................................................................................  78 
11.4.  Record Retention  ...........................................................................................................................................  78 
11.5.  Monitoring of the Study ................................................................................................................................ 78 
12. APPENDIX 3: ADMINISTRATIVE PROCEDURES  ....................................................................................  80 
12.1.  Liabilities  .......................................................................................................................................................  80 
12.2.  Adherence to Protocol  ...................................................................................................................................  80 
12.3.  COVID -19 Response Plan  .............................................................................................................................  80 
12.4.  Statement of Investigator  ...............................................................................................................................  80 
12.5.  Delegation of Investigator Duties  ..................................................................................................................  81 
12.6.  Premature Termination or Suspension of a Study  .........................................................................................  81 
13. APPENDIX 4: PROTOCOL REVIEW AND APPROVALS  .........................................................................  82 
14. APPENDIX 5: LIST OF ABBREVIATIONS  ..................................................................................................  85 
15. APPENDIX 6: CLINICAL LABORATORY EVALUATIONS  .....................................................................  88 
16. APPENDIX 7: COLUMBIA- SUICIDE SEVERITY RATING SCALE (C -SSRS) – 
BASELINE/SCREENING VERSION  .....................................................................................................................  89 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 6 of 95 17. APPENDIX 8: COLUMBIA- SUICIDE SEVERITY RATING SCALE (C -SSRS) – SINCE LAST VISIT 
VERSION  ...................................................................................................................................................................  90 
18. APPENDIX 9: CLINICAL OPIOID WITHDRAWAL SCALE (COWS)  .................................................... 91 
19. APPENDIX 10: CONTRACEPTION GUIDANCE  ........................................................................................  93 
20. APPENDIX 11: PHYSICAL EXAMINATION FORM  ..................................................................................  94 
21. APPENDIX 12: NEUROLOGICAL EXAMINATION FORM  .....................................................................  95 
 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 7 of 95 LIST OF IN-TEXT TABLES  
Table 1 -1 Observed MAD study Exposures and Calculated Margins to Dog NOAEL (3-
month GLP study) ................................................................................................. 22  
Table 1 -2 Observed MAD study Exposures and Calculated Margins to Rat NOAEL (1-month GLP study) ................................................................................................. 22
 
Table 3 -1 Treatment Sequences  ............................................................................................ 28  
Table  5-1  Study Treatments .................................................................................................. 36  
Table 6 -1 Schedule of Activities  ........................................................................................... 40  
Table 6 -2  Vital Sign Recording Schedule ............................................................................ 45  
Table  6-3  Acceptable Windows for Vital Sign Assessments Procedures  ............................. 45  
Table  6-4  Safety ECG Recording Schedule .......................................................................... 46  
Table  6-5  Acceptable Windows for 12 -Lead Safety Electrocardiogram Assessments 
Procedures ............................................................................................................. 46  
Table 6 -6 Digital Electrocardiogram Schedule  ..................................................................... 47  
Table 6 -7 Window Allowance for dECG time points ........................................................... 51  
Table  6-8  Spot Oxygen Saturation Recording Schedule ....................................................... 53  
Table  6-9  Acceptable Windows for SpO2 Assessments Procedures  .................................... 53  
Table 6 -10 Spot End- Tidal CO 2 Recording Schedule ............................................................. 54  
Table  6-11  Acceptable Windows for EtCO2 Assessments Procedures  .................................. 54  
Table 6 -12 Spot Respiratory Rate Recording Schedule .......................................................... 55  
Table  6-13  Acceptable Windows for Respiratory Rate Assessments Procedures  .................. 55  
Table  6-14  Pharmacokinetic Blood Sampling Schedule for Morphine and its Metabolites ... 58  
Table 6 -15 Pharmacokinetic Blood Sampling Schedule for AZD4041 .................................. 58  
Table 6 -16 Acceptable Windows for Timed PK Blood Specimen Collection Procedures ..... 58  
Table 6 -17 Pharmacokinetic Urine Sampling Schedule for AZD4041 ................................... 59  
Table 7 -1 Adverse Event Relationship to Study Drug .......................................................... 61  
Table 8 -1 Pharmacokinetic Parameters in Pl asma ................................................................ 68  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 8 of 95 LIST OF IN -TEXT FIGURES  
Figure 3-1  Study Design ......................................................................................................... 27  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 9 of 95 STUDY SYNOPSIS  
Name of 
Sponsor/Company:  AstraZeneca AB  
Name of Product:  AZD4041  
Title of Study:  A Randomized, Double -blind, Placebo -controlled, Fixed Sequence Study to 
Assess the Effect on Respiratory Drive of Multiple Doses of AZD4041 When 
Co-administered With a Single Dose of Morphine in Healthy Recreational Opioid 
Users  
Study Development 
Phase:  Phase 1 
Objectives:  Primary objective:  
• To assess the effect on respiratory drive of morphine administered after 
multiple doses of AZD4041 compared to morphine administered alone in 
healthy recreational opioid users   
Secondary objectives:  
• To assess the safety and tolerability of multiple doses of AZD4041 when 
co-administered with a single dose of morphine in healthy recreational 
opioid users  
• To assess the pharmacokinetics (PK)  of AZD4041 and morphine in 
healthy recreational opioid users 
• To assess the impact of multiple dose administrations of AZD4041 on the PK of morphine and its metabolites  
• To assess the impact of morphine on steady -state PK of AZD4041  
• To assess the renal clearance of AZD4041 
Endpoints:  Safety:  
Primary  
Incidence of clinically significant changes in respiratory parameters, defined as:  
• Incidence of increased end tidal carbon dioxide (EtCO 2) of at least 
10 mmHg compared to baseline or >50 mmHg (sustained for at least 
30 seconds)  
• Incidence of reduction in SpO 2 to <92% (sustained for at least 
30 seconds)  
Secondary  
• SpO 2 (%) 
 Mean time to reduction in SpO 2 to <92% (sustained for at least 
30 seconds)  
 Mean duration of reduction in SpO 2 to <92% (sustained for at least 
30 seconds)  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 10 of 95  Maximum postdose reduction of SpO 2 adjusted for baseline  
 Mean postdose SpO 2 
• EtCO 2 (mmHg)  
 Mean time to each increased EtCO 2 episode of at least 10 mmHg 
compared to baseline or >50 mmHg (sustained for at least 30  seconds) 
 Mean duration of each increased EtCO 2 episode of at least 10 mmHg 
compared to baseline or >50 mmHg (sustained for at least 30 seconds)  
 Maximum postdose increase in EtCO 2 adjusted for baseline 
 Mean postdose EtCO 2 
• Respiratory rate (breaths/min) 
 Incidence of reduced respiratory rate to <6 breaths/min (sustained for 
at least 30 seconds)  
 Mean time to each reduced respiratory rate episode of <6 breaths/min 
(sustained for at least 30 seconds)  
 Mean duration of each reduced respiratory rate episode of <6 breaths/min (sustained for at least 30 seconds) 
 Maximum postdose decrease in respiratory rate adjusted for baseline 
 Mean postdose respiratory rate  
• Incidence, frequency, severity and relationship of AEs  
• Vital signs (blood pressure, heart rate, and oral t emperature) 
• ECGs (12 -lead safety ECGs, 12 -lead digital ECGs, ECG telemetry)  
• Clinical laboratory test results (clinical chemistry, hematology, 
coagulation, urinalysis)  
• Physical examination findings  
• Neurological examination findings  
• Columbia -Suicide Severity  Rating Scale  (C-SSRS) findings  
• Type of medical intervention used, summarized for each event of significantly increased EtCO
2, reduced SpO 2, or respiratory rate 
Pharmacokinetic:  
Plasma samples will be analyzed to determine concentrations of AZD4041, 
morphine, morphine -6-glucuronide and morphine -3-glucuronide.  
Pharmacokinetic parameters for morphine, morphine -6- glucuronide and 
morphine -3-glucuronide include, but are not limited to, the following:  
Day 1 and Day 15 :  
• Cmax: Maximum observed plasma concentration  
• tmax: Time to maximum observed plasma concentration  
• AUC 0-t: Area under the plasma concentration vs time curve from time 0 to 
the time of the last measurable concentration  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 11 of 95 • AUC 0-∞: Area under the concentration time curve extrapolated to infinity, 
calculated as AUC 0-T + C last/λZ, where C last is the last quantifiable 
concentration at time T last 
• t1/2,z: Terminal elimination half -life, calculated as ln(2)/λ  
• Tlast: Time of last measurable observed concentration  
• CL: Total body clearance, calculated as Dose/AUC 0-∞ (parent drug only)  
• Vz: Volume of distribution based on terminal phase (parent drug only)  
Pharmacokinetic parameters for AZD4041 include, but are not limited to, the 
following:  
Days 2 to  7 and 9 to 14:  
• Ctrough: Pred ose concentration observed immediately prior to the next 
successive dose  
Days 8 and 15:  
• Cmax,ss: Maximum observed plasma concentration 
• tmax,ss: Time to maximum observed plasma concentration  
• Ctrough: Predose concentration observed immediately prior to the next 
successive dose  
• AUC τ: Area under the concentration time curve over the dosing interval at 
steady -state, calculated from 0 to 24 hours (dosing interval)  
• Cav: Average concentration during a dosi ng interval, after the last dose of 
a multiple dose regimen, calculated as AUCτ/τ 
• t1/2, z: Terminal elimination half -life, calculated as ln(2)/λ (Day 15 only)  
• CLss/F: Apparent clearance at steady -state, calculated as Dose/AUC τ  
• Vzss/F: Apparent volume of distribution at steady -state (based on 
terminal phase) 
Urine samples will be analyzed to determine concentrations of AZD4041.  
Pharmacokinetic parameters for AZD4041 include, but are not limited to, the 
following:  
Day 15:  
• Aeτ: Amount of drug excreted in urine  
• fe/F: Cumulative fraction of unchanged drug excreted in urine over the 
dosing interval  
• CL R: Apparent renal clearance  
• t1/2: Elimination half -life 
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 12 of 95 Investigational 
Product, Dose, and Mode of 
Administration 
(proposed): AZD4041 oral solution  (active drug dissolved in vehicle) 
Manufacturer of Drug Substance: AstraZeneca  
Dose:  Mode of administration: Oral 
Placebo, Mode of 
Administration: Vehicle ( ) without active drug 
(AZD4041) 
Manufacturer: MEDISCA  
Mode of administration: Oral 
Opioid, Dose, and 
Mode of Administration Morphine for intravenous (IV) use (Duramorph PF®),  
Manufacturer of Drug Substance:  Hikma Pharmaceuticals USA Inc. 
Dose:  Mode of administration: IV 
Study Design: This is a Phase 1, randomized, double-bli nd, placebo-controlled, 2 fixed sequence 
multiple dose study in healthy male and female recreational opioid users. 
This study will consist of 3 phases: Scre ening and Qualification phase, Treatment 
phase, and Follow-up/Early Termination (ET). 
After a Screening period of up to 27 days (Day -30 to Day -3), eligible subjects 
will be admitted to the clinical research unit (CRU) on Day -2. Subjects will be randomized to 1 of 2 fixed treatment seque nces (28 subjects in Sequence 1, and 
16 subjects in Sequence 2) on Day -1. 
Subjects will be required to present a nega tive urine drug and alcohol screen upon 
admission on Day-2, except for tetrahydro cannabinol (THC). If THC is positive at 
admission, a cannabis intoxication evaluati on will be done by an Investigator, and 
subjects may be permitted to continue in the study at the discretion of an 
Investigator. Subjects will then under go a naloxone challenge where an initial 
0.2 mg IV dose of naloxone hydrochloride (HCl) will be administered. The subject will be observed for signs or symptoms of opioid withdrawal. If there is no evidence of withdrawal within 1 minu te (as assessed by a Clinical Opioid 
Withdrawal Scale [COWS] score of <5), an additional 0.6 mg IV dose of naloxone HCl will be given, and the s ubject will be observed for signs and 
symptoms of withdrawal for 5 minutes (as assessed by COWS). Subjects who 
present symptoms of withdrawal during th e qualification process will be excluded 
from the study and will not be eligib le to enter the Treatment phase. 
In total, subjects will be confined to  the CRU for approximately 20 days from 
Day -2 to Day 18 (until approximately 72 hours following the last study drug 
administration). 
On Day 1, subjects will receive a single   IV dose of morphine. From Day 2 
to Day 15, subjects will receive a  oral dose of AZD4041 or placebo once daily for 14 consecutive administrati ons. On the morning of Day 15, the  
oral dose of AZD4041 or placebo will be combined with a single  IV dose of morphine. 
In order to limit the number of subjects be ing treated with investigational product CCICCI
CCI
CCI
CCI
CCI
CCI
CCICCI
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 13 of 95 on any single day, eligible subjects will be assigned to different subgroups. 
Subgroup sizes should be limited to no more than 8 subjects. Dosing of subgroups 
should be staggered to occur  on different days, with at least 2 days between the 
start of dosing for sequential subgroups.  
A Follow -up visit will occur approximately 7 days after the last drug 
administration.  
Duration of 
Treatment and Subject Confinement: Duration of clinical trial (per subject):  
Screening: Day -30 to Day -3 (up to 27 days)  
Qualification: Day -2 to Day -1 (2 days)  
Treatment: Subjects will be confined to the clinical site for approximately 
20 days, from Day -2 until Day 18 (ie, until 72  hours following the last study drug 
administration)  
Follow -up visit: Subjects will be followed -up approximately 7 days after the last 
drug adm inistration.  
Total study duration: up to 54 days (including Screening)  
Study Population:  Healthy, male and/or female recreational opioid users  
Planned Number 
of Subjects:  Approximately 44 subjects will be randomized (28 AZD4041 + morphine and 16 
Placebo + morphine) to ensure completion of at least 36 subjects (24 AZD4041 + 
morphine, and 12 Placebo + morphine on Day 15).  
Bioanalysis:  Plasma concentrations of AZD4041, morphine, morphine -6-glucuronide and 
morphine -3-glucuronide will be measured by validated bioanalytical methods. 
Urine concentrations of AZD4041 will also be measured by a validated bioanalytical method.  
Safety Analysis:  The safety analysis will be fully detailed in a statistical analysis plan (SAP).  
Pharmacokinetic 
Analysis:  The PK parameters will be determined by non -compartmental analysis using 
appropriate software. The PK analysis will be fully detailed in a SAP.  
Statistical 
Analysis:  The statistical analyses will be fully detailed in a SAP.  
 
 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 15 of 95 1. INTRODUCTION  
1.1. Background 
Opioid use disorder (OUD) is a public health crisis responsible for significant morbidity, 
mortality, and productivity loss. In 2019, approximately 70% of deaths from drug overdose involved opioids ( CDC, 2020), and seven out of 1000 babies (~90 babies each day) were born 
with neonatal abstinence syndrome because their mothers had OUD ( Healthcare Cost and 
Utilization Project, 2016). OUD presents an enormous economic burden in the US estimated to be $170-215 billion per year ( Society of Actuaries, 2019), with the total annual costs to the 
healthcare system in 2018 alone estimated at over $89 billion ( Murphy, 2020). These economic 
burdens and costs to health, quality of life, and public assistance programs are all directly or indirectly related to OUD. There are only 3 Food and Drug Administration (FDA) approved treatments for OUD, all of whic h target μ opioid receptors, which are the major targets for opioid 
actions in the brain. Methadone, buprenorphine, and naltrexone act as an agonist, partial agonist, and antagonist, respectively, at μ opioid receptors. While each is effective with supervi sed use 
and accessory support services, such as counselling, they have limited clinical efficacy and utility (Leslie  et al, 2019 , Mancher et al, 2019). Limitations include intrinsic rewarding 
properties that lead to misuse/diversion (Hall et al, 2 008, Leslie et  al, 2019, Mancher et al, 2019 ), 
unpleasant side effects ( Chen and Ashburn, 2015) that reduce compliance, such as withdrawal 
symptoms ( Mancher et al, 2019), and high residual rates of relapse to drug use 
(Leslie et  al, 2019, Wakeman et al, 2020) . Since OUD and its deleterious consequences are a dire 
national health crisis, the US National Institute on Drug Abuse (NIDA) has identified several high priority drug targets for rapid thera peutic development ( Rasmussen et al, 2019 ). OX
1 
receptor antagonists are high on this list and are considered one of the most promising targets for the development of novel OUD treatments (Rasmussen et al, 2019).  
The neuropeptides orexin A and orexin B (also known as hypocretin 1 and hypocretin 2, respectively) are hypothalamic neuropeptides that act through 2  closely related G protein coupled 
receptors, the OX
1 and OX 2 receptors. Orexin  A has high affinity for both receptors whereas 
orexin B has higher affinity for OX 2 over OX 1 recept ors. Orexin transmission has been 
implicated in a diverse range of physiological functions, including feeding and energy homeostasis ( Sakurai et al, 1998), the sleep/wake cycle ( Gotter et al, 2016), neuroendocrine 
homeostasis, cardiovascular functions ( Samson et al, 2007 ), and motivated behaviours 
(Kodadek and  Cai,  2010). A considerable body of preclinical studies suggests that orexin 
transmission at OX1 receptors plays a major role in the motivation to seek and consume opioids and other drugs of abuse ( Quarta et al, 2009; Porter -Stransky et al, 2017 ; Fragale et al, 2019). 
Indeed, pharmacological blockade of OX
1 receptors or genetic deletion of the gene encoding this 
receptor markedly decreases the consumption of opioids and other addictive drugs such as nicotine and cocaine in laboratory animals without altering their willingness to engage in and seek natural reinfor ces such as food or sex ( Kohlmeier et al, 2013).  
Based on these findings, it has been proposed that excessive orexin transmission at OX1 receptors may play a fundamental role in the development and maintenance of OUD. Recent human brain studies provide compelling support for this hypothesis. Post- mortem human brain 
studies have revealed that the numbers of orexin neurons detected in the lat eral hypothalamus of 
those suffering from OUD are markedly upregulated compared with non- OUD patients 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 16 of 95 (Pantazis et  al, 2020). Rodents treated with opioids also show increased numbers of orexin 
neurons in the brain ( Thannickal et al, 2018). This response is thought to reflect the de novo 
production of orexin peptides by neurons in the hypothalamus in response to opioid use, which 
contributes to the excessive orexin transmission hypothesized to drive the pathologically elevated motivation to seek and consume opioids ( Thannickal et al, 2018). Based on compelling 
preclinical studies and clinical literature, OX
1 receptor antagonists are considered one of the 
most promising novel therapeutic strategies to treat OUD (Rasmussen et al, 2019). Importantly, OX
1 receptors play a similar role in regulating the addiction -related actions of nicotine, 
psychomotor stimulants, and alcohol, raising the possibility that OX 1 receptor antag onists may 
have utility for the treatment of addiction across different classes of abused drugs.  
1.2. Study Rationale  
AstraZeneca  (AZ) , in partnership with Eolas Therapeutics, Inc, is developing an OX 1 receptor 
antagonist, AZD4041, which demonstrates favourabl e drug -like physiochemical properties. The 
half maximal inhibitory concentration (IC 50) for AZD4041 at OX 1 and OX 2 receptors is 5  nM 
and > 5000 nM, respectively. The high level of selectivity between the OX 1 and OX 2 receptors 
substantially reduces the potential for hypnotic effects of this OX 1 antagonist since it is thought 
that the OX 2 receptor is primarily responsible for the effects of orexin on arousal 
(Boutrel et  al, 2005). Consistent with this possibility, AZD4041 does not induce sleep- like 
electroencephalogram (EEG) waveforms in rodents across a broad range of doses. AZD4041 
does not measurably inhibit the activity of cytochrome P450 enzymes or human ether-a-go-go-related gene (hERG) channels nor does it have significant actions at any non- OX
1 receptor 
targets so far screened. AZD4041 is highly brain penetrant in nonhuman primates and has relatively slow rates  of clearance and high levels of oral bioavailability in dogs. AZD4041 
demonstrates in vivo efficacy, as measured by reduced oxycontin- seeking behaviours, in 
rodents - at relatively low exposures. Further details of these studies are provided in the  
Invest igator’s Brochure  (AZD4041 Investigator’s Brochure ).  
AZD4041 may therefore provide an attractive treatment option for OUD. 
This study is being primarily conducted to assess the effect on respiratory drive of morphine 
administered after multiple doses of AZD4041 compared to morphine administered alone in 
healthy recreational opioid users. This study will also assess the safety, tolerability, and pharmacokinetics ( PK) of multiple doses of AZD4041when co-administered with single dose of 
morphine in healthy recreational opioid users. The PK of AZD4041 and morphine in healthy recreational opioid users will be assessed. Moreover, t he impact of multiple dose administrations 
of AZD4041 on the PK of morphine and metabolites will also be assessed, including the impact of morphine on steady-state PK of AZD4041. 
1.3. Risk/Benefit Assessment  
1.3.1. Known Potential Benefits  
AZD4041 has shown significant efficacy in oxycodone self- administration s tudies in rats. In 
addition, AZD4041 reduces cue-induced reinstatement of oxycodone seeking behaviours and 
blocks craving-like behaviours in a rat model of oxycodone withdrawal. Supporting the feasibility of developing a safe and potent OX1 receptor antagonist for OUD is the fact that two dual OX1/OX2 receptor antagonists (suvorexant and lemborexant, so-called DORAs) have 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 17 of 95 already received FDA approval as sleep -promoting agents. The sleep- promoting actions of 
DORAs primarily reflect their ability to block th e OX2 receptors. Neither of these DORAs show 
any evidence of concerning side- effects in the general population despite their wide -spread use. 
This suggests that novel OX1 receptor selective antagonists, devoid of the sleep -promoting 
effects that limit the utility of DORAs for non -sleep -related disorders such as OUD, are unlikely 
to be associated with mechanism  related toxicity in humans ( O’Connor et al, 2010) . It therefore 
appears that AZD4041 could represent a novel strategy in the treatment of addictive disorders 
such as OUD, where it has the potential to address a significant unmet need.  It is thought 
unlikely that the recreational opioid users participating in the current study  will benefit from 
taking the AZD4041 study treatment. However,  it is anticipated that the study will provide 
important safety and PK data that will inform the scientific  rationale for further development of 
AZD4041 as a potential treatment o f OUD.  
1.3.2. Important Potential Risks  
Potential risks of AZD4041 based on data observed in animal studies include thymus effects (including atrophy), male reproductive tract effects, and arrhythmias.  
In nonclinical studies, AZD4041 has been evaluated in repeat dose toxicity studies of 1 month duration in rats, and in studies of 1- and 3-months duration in dogs; in in vitro and in  vivo 
genotoxicity studies; and in an in vitro phototoxicity study. Safety pharmacology studies assessing effects on the respiratory, cardiovascular, central and perip heral nervous systems, and 
in vitro effects on hERG have also been conducted. 
AZD4041 was negative in the Good Laboratory Practice ( GLP ) in vitro  Ames and chromosome 
aberration studies and in the GLP in vivo micronucleus study. AZD4041 was also negative in an 
in vitro 3T3 phototoxicity assay. 
No significant effects of AZD4041 were noted on the central nervous system ( CNS ), locomotor 
function, or motor coordination in rats. In the sleep/wake and EEG study in rats, AZD4041 significantly increased wakefulness at the expense of non-rapid eye movement sleep when compared with control. In a respiratory study conducted in rats, no significant effects were seen except at the highest dose of 100 mg/kg where lower tidal volume (11% below) was noted when compared with vehicle control at baseline. A similar effect was noted with AZD4041 alone in a 
study wit h a morphine challenge; increased respiratory depression was also noted following 
morphine administration after AZD4041 . For the current clinical study, effects on 
sleep/wakefulness will be assessed via AE reporting. Only healthy subjects will be enrolled in the current study and subjects with respiratory co- morbidities will be excluded. In addition, vital 
signs will be assessed at regular intervals after dosing (See Sc hedule of Activities, Table  6-1).  
In the hERG assay, the IC
50 for AZD4041 was calculated to be 219.3 µM. In a panel of in vitro 
electrophysiological assays of recombinant human voltage- gated cardiac ion channels 
(hKv4.3/hKChIP2.2 – ITO; hKv7.1/hKCNE1 – IKS; hNav1.5 – INa; hKV1.5; hCav3.2; hHCN4), AZD4041 had no activity. Therefore, a risk of QT prolongation is not expected with AZD4041. In the dog cardiovascular study, sustained durations of premature ventricular contractions, beginning approximately 7 hours after dosing and continuing up to 24 hours after dosing, were noted in 1 dog only at the highest dose of 100 mg/kg. The onset of the changes was soon after the approximate T
max (average of 4.6 hours) in the dog study. Hemodynamic 
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 18 of 95 parameters were largely unaltered and were maintained in the phys iological range of heart rate 
(HR) and blood pressure (BP). In a dog 14-day investigative study, lower HR, with associated 
longer PR and QT intervals, were recorded at 60  mg/kg/day; there were no changes in the rate-
corrected QT interval and no arrhythmias were noted. There were no changes in ECG rhythm or 
waveform morphology attributable  to AZD4041. Furthermore, th ere were no effects on ECG 
parameters or morphology in th e 1-month dog study in which dogs received up to 60 mg/kg/day. 
In the 1-month GLP toxicity stud ies, the key findings were lo wer thymus weights and thymic 
atrophy in female dogs, a nd effects on the male reproductive tract in dogs. Other findings were 
increased liver weight, attribut ed to hepatocellular hypertrophy in rats and dogs; and increased 
thyroid weight, attributed to follicular cell hypertrophy and reco rded in rats only. Due to the 
minimal severity and adaptive nature of the ch anges, the hepatic and thyroid changes were 
considered not adverse. Lower thymus weights we re noted for female dogs and correlated with 
increased severity of thymic at rophy, characterized by decreased th ickness of the cortex relative 
to the medulla, at the high dose. Taken together, the effect on thymus wei ght combined with the 
microscopic finding of atrophy was c onsidered to be adverse. Th ere were no effects on organ 
weight or microscopic pathology noted for the thymus at the end of the recovery period, 
indicating recovery. Effects on the thymus were not recorded in the dog 3-month study. 
In the dog 1-month study, effects in the form of tubular degeneration/ atrophy of the testes, 
reduced luminal sperm in the epididymides, and immaturity and/or single cell necrosis of the 
prostate glands, with associated  effects on organ weight, were noted. There was some evidence 
of recovery at the end of the 4- week recovery period, in that findi ngs were of a lesser severity 
compared to the main test and/or of a similar inci dence/severity to the concurrent controls. In the 
3-month dog study, there were changes in the pr ostate (atrophy and lowe r weight) and testes 
(vacuolation of Leydig cells) and epididymides (e pithelial vacuolation). In comparison to the 
1-month study, these changes were  generally not as marked, cons idered to be non-adverse and 
followed longer term administration at genera lly higher exposures. Following 1 month of 
administration, the no-observed-adverse-eff ect-level (NOAEL) was established as 
100 mg/kg/day in the rat and 10 mg/kg/day in the dog. The NOAEL in the dog 3-month study 
was 60 mg/kg/day. There is evidence that OX 1 receptors are expresse d in dog seminiferous 
tubules ( Ligouri, 2018 ) and are involved in the re gulation of spermatogenesis 
(Barreiro et al, 2005 , Hakovirta et al, 1999 , Yan et al, 1999 , Yan et al, 2000 ), which may 
demonstrate a potential link be tween the pharmacologi cal action of AZD4041 and the findings in 
the dog. It should be noted that si milar findings were not seen af ter 14 days in the dog dose range 
finding study, albeit with smaller numbers. No e ffects on the male reproductive tract were seen 
in the rat 1-month GLP toxicity study. 
The AZD4041 single ascending dos e (SAD) study (Protocol D 7460C00001) was completed for 
6 cohorts of healthy volunteer wi th N= 8 subjects per cohort rando mly assigned to receive either 
AZD4041 or placebo (N= 6 AZD4041 and N=2 placeb o). Single oral doses explored in the SAD 
study were . There were  no severe treatment 
emergent adverse events (TEAEs), severe adve rse events (SAEs) or TEAEs leading to study 
discontinuation over the course of  the study. There were no appare nt dose-related trends with 
respect to the reporting of AEs. The most common TEAEs to be repor ted in subjects treated with 
AZD4041 include ventricular tac hycardia (5.6%), back pain ( 5.6%), nausea (2.8%), vomiting CCI
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 19 of 95 (2.8%) and dyspnea (2.8%). No clin ically significant changes have  been reported for laboratory 
safety, vital sign, or 12- lead ECG parameters. 
Two short episodes of non-sustained ventricular tachycardia (NSVT) were observed in the SAD 
study in subjects who had received AZD4041, 1 each in Cohort 4 ( ) and Cohort 5 ( ), 
observed at 8 hours and 6.5 hours po stdose, respectively. The NSVT events were asymptomatic 
and resolved spontaneously. Across the full dos e range of the study, no tr ends for changes or 
prolongations in ECG parameters including QTcF, QR S, and PR interval; or changes in the QRS 
and T-wave morphology that woul d indicate, for example, hERG -related potassium or sodium 
channel effects. There was no evidence for systematic changes in HR. In 12-lead ECG telemetry files of the 2 subjects with NSVT, no notable  QTcF prolongation or QRS interval prolongation, 
or changes in QRS or T wave morphologies we re found. No subject in the study has had a QTcF 
> 450 msec. Only 1 subject in the study had an increase in QTcF > 30 msec (32 msec), which 
occurred at 6 hours postdose. Neither  subject appears to be different  from the rest of the subjects 
in their cohort based on exposure pa rameters (Area under the curve, C
max, Tmax, concentration at 
6 and 8 hours).  
The multiple ascending dose (MAD) study of  AZD4041 (Protocol D7460C00002) has recently 
completed in Canada and interim data [blinded to treatment assignment] are available pending 
database lock. Three dose levels of AZD4041 were explored ( ) in healthy volunteers, who received repeat once-daily doses fo r 14 days (N=12 s ubjects per cohort 
with N=9 receiving AZD4041 and N=3 receivi ng placebo). Cardiac monitoring included 
extended periods of ECG telemetry and Holte r ECG recording. Dose escalation proceeded 
uneventfully across the cohor ts. Exposures for AZD4041 (C
max and AUC) increased in an 
approximate dose proportionate manner fro m  and remained within the range 
predicted. Maximum exposures (T max) were observed between 0.5 to 3.0 hours postdose. The 
effective half-life for AZD4041 ranged from 18.6 to 21.3 hours, comparable to that observed in 
the SAD study. Accumulation ratios over the dosing period ranged from 1.27 to 1.59 for C max 
and from 1.66 to 1.81 for AUC. Steady state exposures (C trough) were achieved at Day 6 for the 
 dose and Day 8 for the  dose levels . With respect to the pre-defined 
limits of human exposure and exposure prediction s for potential doses higher than , further 
dose escalation was not undertaken. No medically im portant tolerability or safety issues were 
raised by the dose escalation committee with re spect to any of the sa fety endpoints (including 
vital signs, 12-lead ECGs, safety blood tests and urinalysis) duri ng the course of the study. There 
were no observed SAEs or dose-limiting toxicities. Adverse events were mild in nature and were 
mostly resolved by checkout. The most common TEA Es, reported in two or more subjects, were 
NSVT (observed for two subjects in Cohor t 1 [ placebo] and one subject in Cohort 3 
[ placebo]), post lumbar puncture syndrome, medical device site reaction, headache, and 
nausea. The NSVT events were detected on Ho lter ECG monitoring; th ey were non-sustained 
and resolved spontaneously. One of the subjects  with NSVT in Cohort 1 reported palpitations on 
Day 2 and was withdrawn by the Investigator before  dosing on (Day 3) for safety reasons due to 
these adverse events. In Cohort 3 placebo), one episode of NSVT was observed on 
Day 2, ~7.5 hours after dosing. The event was asym ptomatic and resolved  without intervention 
or recurrence. No clinically significant cha nges or trends for changes were observed for 
laboratory safety assessments,  vital sign parameters, or EC G intervals in the MAD study. 
Overall, AZD4041 was considered to have a good safety and tolerability profile when CCI CCI
CCI
CCI
CCI
CCICCI
CCICCI
CCI
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 20 of 95 administered to healthy volunteers in repeat oral doses ( once daily for 14 days) up to  in 
the MAD study. A detailed summary of the availabl e human safety and PK data is provided in 
the Investigator’s Brochure ( AZD4041 Investigator’s Brochure ). 
There is limited class in formation on the safety profile of selective OX1 recep tor antagonists in 
humans. While two DORA (suvorex ant and lemborexant) are a pproved for the treatment of 
insomnia, no selective OX1 receptor antagonists have been approved for any indication so far. 
Limited safety data are available for the single and multiple dosing studies with 2 selective OX1 
receptor antagonists (ACT-539313 [ Kaufmann et al, 2019 , Kaufmann et al, 2021 ] and 
JNJ-61393215 [ Salvadore et al, 2019 ]). Both appeared to be well tolerated in these initial studies 
with the most common reported AEs being somnolence and headache.  
The following safety measures will be monitored continuously for signs of  respiratory depression 
from up to 1 hour prior to dosing up to approxim ately 6 hours following dosing in the Treatment 
phase: 
x End-tidal carbon dioxide  (EtCO 2) monitoring 
x Blood oxygen saturation (SpO 2) monitoring 
x Respiratory rate monitoring 
Safety measurements of EtCO 2 and SpO 2 are accepted endpoints for the evaluation and 
monitoring of respiratory func tion, change in oxygenation, a nd change in ventilation ( Linko and 
Paloheimoi, 1989 , Jabre et al, 2009 , Manifold et al, 2013 , and Waugh et al, 2011 ). Monitoring 
EtCO 2 has been shown to be more sensitive in the detection of respiratory depression than 
monitoring respiratory rate and pulse oximetry alone ( Goli et al, 2012 ). In the clinical setting, 
respiratory depression is usually  described in terms of decrease d respiratory rates, decreased 
SpO 2 levels, ( Cashman et al, 2004 ) or elevated EtCO 2 levels and, therefore, these measures are 
appropriate to monitor for respiratory depression in th e context of this study. 
Serious, life-threatening, or fa tal respiratory depression may occur with use of morphine 
(Infumorph Label 2019 ). Subjects will be mon itored for respiratory depression in a fully 
equipped and staffed environment. Details of m itigating signs of respiratory depression and 
medical interventions are provided in Sections 6.1.15  and 6.1.16 .  
Additional safety measures implemented at predose and specified timepoints postdose will 
include the collection and documentation of AEs a nd vital signs (ie, syst olic and diastolic BP, 
HR, and oral temperature), respiratory rate, and SpO 2. Cardiovascular risk  mitigations include 
appropriate eligibility criteria, individual and st udy-level stoppi ng criteria; and a sufficiently 
stringent level of cardiac monitoring will be re tained for the current clinical study protocol, 
similar to MAD study protocol; 12-lead safe ty ECGs, alongside extended periods of ECG 
telemetry and Holter monitoring have been im plemented to monitor for any arrhythmias. 
Subjects will be determined as eligible for inclus ion into the study based on measures of clinical 
laboratory testing, vital signs, medical history, Columbia-Sui cide Severity Rating Scale 
(C-SSRS), physical examination, and ECG. CCI
Protocol No: D7460C00003  
Altasciences Project No: AZN-P1-265
Version 2.0 (Amendment 01), 16-SEP-2022 Page 21 of 95
Justification for Dose selection
The rationale for the planned AZD4041 dose leve l ( ) for the current study is based on an 
understanding of data accumulated across non-clinical studies and cl inical experience to-date and
summarised as follows:
xAZD4041 was found to have a good safety prof ile and to be well tolerated by healthy 
volunteer subjects administer ed single oral doses up to  in the completed single -
dose study (D7460C00001) and up to  administered once daily for 14 days in the repeat-dose study (D7460C00002). The observe d PK data in the studies indicate 
dose-related and approximately dose-proportiona l exposures. Steady state exposures were 
achieved after 6 to 8 days of repeat dosi ng. The observed steady-state exposures are 
aligned with those previous ly predicted from simulations  and modelling. Exposures 
observed at the  repeat dose level in th e MAD study do not exceed those previously 
achieved at the highest ( ) single dos e level explored in the SAD study (see 
Investigator’s Brochure for deta ils of human safety and PK). 
xSafety margins for AZD4041 have been based on PK data observed in the MAD study at 
the  dose level and calcula ted with respect to exposure data achieved at the 
NOAEL exposures observed in the 3-month dog GLP study (60 mg/kg) and the 1-month 
rat GLP study (100mg/kg). The 3-month study is  considered to provide the most robust 
and comprehensive assessment of the ef fects of AZD4041 in the dog. The lowest 
NOAEL exposures from the repeat dose t oxicology studies are from the rat 1-month 
study (see Table 1-1 and Table 1-2 ). The relevant safety margins at the proposed  
dose level are therefore cons idered to be 22-fold and 13.2-fold for maximum observed 
concentration (free C
max, ss ) and total exposure at steady-state (free AUC tau.ss), 
respectively. 
xConcentrations of AZD4041 that are predicte d to be therapeutically efficacious and 
relevant to humans with opi oid-use disorder have been estimated by extrapolation of 
exposures at a dose level which is effective in a rat oxycodone withdrawal model. In the 
rodent model, a total plasma  exposure of 523 nM and a free plasma exposure of 147 nM 
were estimated at an efficacious AZD4041 dose of  (PO). Analysis of PK data 
from the human MAD study indicates  that it is possible to ac hieve comparable systemic 
exposures that are predicted to achieve efficacy. In humans, once daily repeat  
doses of AZD4041 for 14 days provided a mean total C maxof 1828 nM (941 ng/mL) and 
free C max of 327 nM (168.4 ng/mL). Likewise, human study provided a mean total C trough
concentration of 697 nM (359 ng/mL) and free C trough concentration of 125 nM 
(64ng/mL) for  dose at steady-state. Preliminary evaluation of AZD4041 steady 
CNS penetration at the  dose level in the MAD study indicate  a total brain-to-
unbound plasma drug partition coefficient (K p,uu) of 0.295. Corresponding estimates for 
the brain free concentrations (mean C max.ss = 97 nM and C trough.ss  = 39 nM) are 
comparable to the estimated free brain exposure of AZD4041 ( 25 nM) predicted to confer 
efficacy in the rodent oxycodone withdrawal model. Furthermore, measured free brain 
concentrations in humans following dosing of   to steady state exceed the in vitro 
inhibitory constant for AZD4041 at the human  orexin 1 receptor (Ki = 1.5 to 7.9 nM) and CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCICCI
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 22 of 95 are in line with exposures where OXR1 targ et engagement would be expected (see 
Investigator’s Brochure  for details). 
x The proposed  dose level for AZD4041 is c onsidered appropriate for the current 
study, because (1) the expected steady-state exposures at  provide coverage over a 
range of exposures that are predicted to be therapeutically efficacious for the treatment of 
opioid use disorder in humans, and (2), ther efore provides for a r obust evaluation of the 
potential for AZD4041 to interact with single dos es of morphine at a dose level that is 
considered to be at the higher limit of plau sible efficaciou s and therapeutically-relevant 
doses. 
Table 1-1 Observed MAD study Exposures and Calculated Margins to Dog NOAEL 
(3-month GLP study) 
Clinical dose  
(mg) Total C max.ss 
(ng/mL)  Human Free  
Cmax.ss 
(ng/mL) Total 
AUC tau.ss 
(ng·h/mL) Human Free 
AUC tau.ss 
(ng·h/mL) Free C max.ss 
margin to dog  
NOAEL Free AUC tau.ss 
margin to dog  
NOAEL 
232 41.5 3030 540 91 105 
478 85.6 6290 1125.9 44 50 
941 168.4 12609 2257.1 22 25 
A human plasma protein binding value of 17.9% has been applied to calculate human free C max and AUC tau. 
For the NOAEL values, combined sex (male and female) toxicokinetic data have been utilized. 
Dog NOAEL (60 mg/kg) exposures for free C max (3,764 ng/mL) and free AUC last (56,883 ng.h/mL) were used to 
calculate safety margins. 
Human exposures for the planned  dose level should not exceed 1/10th of the NOAEL in the 3-month dog 
study. Based on observed human exposures, free C max.ss is not expected to exceed 376 ng/mL and free AUC tau.ss is not 
expected to exceed 5688 ng.h/mL. 
Table 1-2 Observed MAD study Exposures and Calculated Margins to Rat NOAEL 
(1-month GLP study) 
Clinical dose  
(mg) Total 
Cmax.ss  
(ng/mL)  Human 
Free  
Cmax.ss 
(ng/mL) Total 
AUC tau.ss 
(ng·h/mL) Human 
free 
AUC tau.ss 
(ng·h/mL) Free C max.ss 
margin to dog  
NOAEL Free AUC tau.ss 
margin to dog  
NOAEL 
232 41.5 3030 540 90 55 
478 85.6 6290 1125.9 44 26 
941 168.4 12609 2257.1 22 13.2 
A human plasma protein binding value of 17.9% has been applied to calculate human free C max and AUC tau. 
For the NOAEL values, combined sex (male and female) toxicokinetic data have been utilized. 
Rat NOAEL (100 mg/kg) exposures for free C max (3,751 ng/mL) and free AUC last (29,793 ng.h/mL) were used to 
calculate safety margins. 
Human exposures for the planned  dose level should not exceed 1/10th of the NOAEL in the 1-month rat 
study. Based on observed human exposures, free C max.ss is not expected to exceed 375 ng/mL and free AUC tau.ss is 
not expected to exceed 2979 ng.h/mL. 
x The dose of morphine administered in this study is not expected to present any significant 
risk to the subjects ( Duramorph Label 2010 ). In adults, the r ecommended initial IV CCI
CCI
CCI
CCI
CCI
CCI
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 23 of 95 morphine dose is between 2 mg to 10 mg/ 70 kg of body weight. Doses of morphine of up 
to  have been safely administered in travenously in non-dependent, recreational 
opioid users ( Stoops et al, 2010 , Webster et al, 2011 ). A supratherapeutic dose of 
morphine was selected for this study to in crease the likelihood of evaluating effects on 
respiratory parameters. The dose of  IV wa s selected for this study as it has been 
safely administered in prior studies of opi oid experienced, non-de pendent recreational 
users ( Osterlund et al, 2001 , Osterlund et al, 1999 , Thompson et al. 1999 , Skarke et al, 
2003 , Bailey et al, 1991 ).  
x The potential for AZD4041 (  administered on ce daily for 14 days) to interact with 
single doses of morphine at a metabolic level is considered to be low in this study. In 
vitro studies indicate that  AZD4041 shows minimal or no inhibition across a panel of 
cytochrome P450 (CYP) enzymes with IC 50 values all determined to be > 30 PM. 
AZD4041 is considered to pose a low risk as a perpetrator of drug- drug interactions via 
inhibition of transporters such as OATP1B1 (IC 50 = 38 PM), BCRP (IC 50 = 48 PM) or 
P-glycoprotein (IC 50 = 282 PM) and poses a low risk as a perpetrator via induction of 
CYP enzymes (4-fold and 100 fold i nduction of CYP1A2 and CYP34 at 30 PM, 
respectively). While CYP3A4 contributes to >9 0% of AZD4041 metabolism in vitro, it is 
not expected that single doses of mor phine ( ) will appreciably affect the 
metabolism or cleara nce of AZD4041. 
1.3.3.  Risk/Benefit Conclusion 
The hepatic and thyroid effects obs erved in the preclinical studies were considered minimal and 
adaptive; and thymic atrophy was noted to have fu lly recovered at the end of the recovery period. 
On the basis of data observed in the safety  pharmacology study, the effects of AZD4041 co-
administered with single doses of  morphine, on respiratory drive will be evaluate d and monitored 
in the clinical st udy by measuring EtCO 2, O2 saturation, and respiratory rate.  
Cardiac arrhythmia remains a potential  risk during the ongoing expl oratory clinical development 
of AZD4041 and appropriate risk mitigation measur es have been implemented into the protocol.  
Women of non-childbearing poten tial may be enrolled into the study. Inclusion of fertile (non-
vasectomised) males in the study is justifie d on the basis that the 3-month dog GLP study 
provides the most robust and comprehensive evaluation of AZD4041 on the male reproductive 
tract in this species. A NOAEL has been identif ied in the dog study with respect to toxicologic 
effects seen in the prostate , testes and epididymides. Hu man exposures to AZD4041 at 
steady-state for the planned dose level ( , once daily for 14 days) are not expected to exceed 
1/10th of the NOAEL in the 3-month dog study. These exposures are also significantly lower 
than those identified at the NOAEL in the rat 1-month study. No reproductive effects have been 
seen in the rat 1-month GLP study. In addi tion, the planned dose of AZD4041 has been 
evaluated previously in a 14-day MAD clinical  study; the dosing reg imen was generally well 
tolerated and no significant medi cal or safety concerns were  raised by the dose escalation 
committee. 
Based on the considerations regarding the pot ential risks of AZD4041, exposure of healthy 
volunteer subjects with a histor y of recreational opioid use to  repeat doses of AZD4041 is 
considered justifiable in relation to the signifi cant unmet need to deve lop improved efficacious CCI
CCI
CCI
CCI
CCI
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 24 of 95 treatments for opioid-use disorder. It is expected that the safety, tolerability and PK data acquired 
in the cur rent study in health y volunteer who are opioid users, will provide a scientific basis and 
rationale for the subsequent evaluation of AZD4041 in patients with OUD. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of AZD4041 may be found in the Investigator’s Brochure ( AZD4041 
Investigator’s Brochure ). 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 26 of 95 OBJECTIVES  ENDPOINTS  
 Mean postdose respiratory rate  
• Incidence, frequency, severity , and 
relationship of AEs  
• Vital signs (blood pressure, heart rate, and 
oral temperature)  
• ECGs (12-lead safety ECGs, 12-lead d igital 
ECGs, and ECG t elemetry)  
• Clinical laboratory test results (clinical chemistry, hematology, coagulation, urinalysis) 
• Physical examination findings  
• Neurological examination findings  
• C-SSRS findings  
• Type of medical intervention used, summarized for each event of significantly increased E tCO
2,  reduced SpO 2, or respiratory 
rate 
To assess the PK of AZD4041 and morphine in 
healthy recreational opioid users  Plasma concentrations as well as PK parameters for 
AZD4041 and morphine and its metabolites as 
described in Section 8.4 
To assess the impact of multiple dose 
administrations of AZD4041 on the PK of 
morphine and its metabolites  Plasma concentrations as well as PK parameters for 
AZD4041 and morphine and its meta bolites as 
described in Section  8.4 
To assess the impact of morphine on 
steady -state PK of AZD4041  Plasma concentrations as well as PK parameters for 
AZD4041 and morphine and its metabolites as 
described in Section  8.4 
To assess the renal clearance of AZD4041  Urine concentrations as well as PK parameters for 
AZD4041 as described in Section  8.4 
Abbreviations: AE = adverse event; C -SSRS = Columbia- Suicide Se verity Rating Scale; ECG = electrocardiogram 
EtCO2 = end tidal carbon dioxide; PK = pharmacokinetic; SpO2 = oxygen saturation.  
3. STUDY DESIGN  
3.1. Overall Study Design 
This is a Phase 1, randomized, double- blind , placebo -controlled, 2 fixed sequences,  multiple 
dose study in healthy male and/or female recreational opioid users.  
This study will consist of 3 phases: Screening and Qualification, Treatment phase , and 
Follow-up (s ee Figure 3-1).  
Protocol No: D7460C00003  
Altasciences Project No: AZN-P1-265
Version 2.0 (Amendment 01), 16-SEP-2022 Page 27 of 95Figure 3-1 Study Design
After a Screening period of up to 27 days (Day - 30 to Day -3), eligible subjects will be admitted 
to the clinical research unit (CRU) on Day - 2. Subjects will be randomized to 1 of 2 fixed 
treatment sequences (28 subjects in Sequence 1, and 16 subjects in Sequence 2) on Day -1. 
Subjects will be required to present a nega tive urine drug and alcohol screen upon admission on 
Day-2, except for tetrahydrocannabinol (THC).  If THC is positive at admission, a cannabis 
intoxication evaluation will be done by an Investigator, and s ubjects may be permitted to 
continue in the study at the discretion of an Investigator. Subjects will then undergo a naloxone 
challenge where an initial 0.2 mg intravenous (IV ) dose of naloxone hydrochloride (HCl) will be 
administered. The subject will be observed for signs or symptoms of opioid with drawal. If there 
is no evidence of withdrawal within 1 minute (as assessed by a Clinical Opioid Withdrawal Scale 
[COWS] score of <5), an additional 0.6 mg IV  dose of naloxone HCl will be given, and the 
subject will be observed for signs and symptoms of withdrawal for 5 minutes (as assessed by 
COWS). Subjects who present symp toms of withdrawal during the qualification process will be 
excluded from the study and will not be elig ible to enter the Treatment phase. 
In total, subjects will be confined to the CRU for approximately 20 days from Day -2 to Day 18 
(until approximately 72 hours following the last study drug administration).  
On Day 1, subjects will receive a single IV  dose of morphine. From Day 2 to Day 15, 
subjects will receive a  oral dose of AZ D4041 or placebo once daily for 14 consecutive 
days. On the morning of Day 15, the  oral do se of AZD4041 or placebo will be combined 
with a single  IV  dose of morphine.
In order to limit the number of subjects being treated with investigational product (IP) on any 
single day, eligible subjects should be assigne d to different subgroups. Subgroup sizes should be 
limited to no more than 8 subjects. Dosing of  subgroups should be staggered to occur on 
different days, with at least 2 days between the start of dosing for sequential subgroups.  
A Follow-up visit will occur approximately 7±2 d ays after the last st udy drug administration. 
The schedule of activities of  the study is described in Table 6-1.
CCI
CCI
CCICCI
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 28 of 95 3.2. Study Treatments 
The following treatments will be administered according to  Table 3-1 . 
x Test: A single  of AZD4041 oral solution will be 
administered once daily from Day 2 to Day 15 according to the ra ndomization schedule. 
x Placebo : Vehicle without active drug (AZD4041) will be orally administered once daily 
from Day 2 to Day 15 according to the randomization schedule. 
x Morphine : A  of morphine will be intravenously 
administered on Days 1 and Day 15 only. 
Table 3-1 Treatment Sequences 
 Day 1 Days 2 to 14 Day 15a 
Sequence 1 
(n=28)  Morphine   AZD4041 
once daily  AZD4041 +  
Morphine  
Sequence 2 
(n=16)  Morphine  Placebo 
once daily Placebo +  Morphine 
a. The assigned treatment (AZD4041 or Placebo) will be administ ered orally immediately (within 1 minute) after 
the end of morphine infusion. 
4. SUBJECT POPULATION 
Subjects meeting all the inclusion cr iteria and none of the exclusi on criteria at Screening may be 
eligible for participation in th is study. Continued eligibility will be assessed upon admission to 
the clinical site, prior to the first study drug administration. 
Screen failures are defined as participants who consent to participate in the clinical trial but are 
not subsequently randomly assigned to the stud y intervention or enrolled in the study. 
4.1. Inclusion Criteria 
1. Recreational opioid user, not currently consider ed to have moderate or severe substance 
use disorder for opioids (based on the Di agnostic and Statistical Manual of Mental 
Disorders, 5th Edition [DSM-5] criteria) and has experience with opioid use for non-
therapeutic purposes (ie, for psychoactive ef fects) on at least 10 occasions in their 
lifetime and at least 1 occasion in the last 12 weeks prior to Screening 
2. Provision of signed and dated in formed consent form (ICF) pr ior to the initiation of any 
protocol-specific procedures 
3. Stated willingness to comply with all study proc edures and availability for the duration of 
the study 
4. Healthy adult male or female, 18 to 55 years of age, inclusiv e, prior to the first study drug 
administration 
5. Body mass index (BMI) within 18.0 kg/m2 to 35.0 kg/m2, inclusive, and body weight at 
least 50 kg at Screening CCI
CCI
CCI
CCICCI CCI CCI
CCI
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 29 of 95 6. A female study subject of non- childbearing potential must meet 1 of the following 
criteria:  
(1) Physiological postmenopausal status, defined as the following: 
a) absence of menses for at least 1 year prior to the first study drug administration 
(without an alternative medic al condition); and  
b) Follicle stimulating hormone (FSH) levels ≥ 40 mIU/mL at Screening  
AND/ OR 
(2) Surgical sterile, defined as those who have had  hysterectomy, bilateral oophorectomy 
and/or bilateral salpingectomy, or bilateral tubal ligation. Women who are surgically sterile must provide documentation of the procedure by an operative report, ultrasound, or other verifiable documentation . 
7. If male , must agree to use a highly effe ctive method of contraception (see APPENDIX10  
for contraception guidance) when engaging in sexual activity and must not donate sperm during the study and for at least 4 months (120 days) after the last dose of study medication  
8. Healthy  in the opinion of an Investigator , as determined by no clinically significant 
findings from medical history, physical examination, 12 -lead ECG, vital signs, oxygen 
saturation (SpO
2), respiratory rate,  or clinical laboratory (including hematology, 
coagulation, clinical chemistry, urinalysis, and serology [S creening visit only]) at 
Screening visit and /or prior to the first study drug administration  
4.2. Exclusion Criteria  
1. Female who is pregnant according to the pregnancy test at Screening  or prior to the first 
study drug administration 
2. Male subjects with a history of oligospermia or azoospermia or any other disorder of the reproductive system 
3. Male subjects who are undergoing treatment or investigation for infertility  
4. History of moderate or severe substance or alcohol use disorder (excluding nicotine and 
caffeine) within the past 2 years, as defined by the DSM-5 
5. History of any significant psychiatric disorder according to the criteria of the DSM -5 
which, in the opinion of the Investigator, could be detrimental to subject safety or could compromise study data interpretation.  
6. History of significant hypersensitivity to AZD4041, morphine and/or other opioids, naloxone, or any related products (includi ng excipients of the study formulations) as well 
as severe hypersensitivity reactions (like angioedema) to any drugs  
7. History of any significant disease, including [but not necessarily limited to] significant 
hepatic, renal, cardiovascular, pulmonary, hematologic, neurological, psychiatric, gastrointestinal, endocrine, immunologic, ophthalmologic, or dermatologic disease of any etiology (including infections) identified at S creening  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 30 of 95 8. Presence or history of significant gastrointestinal, liver or kidney disease , or any other 
condition [including those that may result from surgery] that is known to interfere with 
drug absorption, distribution, metabolism, or excretion, or known to potentiate or 
predispose to undesired effects.  
9. Oxygen saturation (SpO 2) below 95% at Screening or prior to first study drug 
administration  
10. Any abnormal vital signs, after no less than 5 minutes rest  (supine position), as defined in 
the list below, at Screening  and/or prior to the first study drug administration . Out of 
range test may be repeated once for each visit at the discretion of the Investigator.  
• Systolic BP  < 90 mmHg or > 140 mmHg  
• Diastolic BP  < 50 mmHg or > 90 mmHg  
• HR < 45 or > 90 beats per minute (bpm)  
11. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12- lead EC G, which in the 
Investigator’s opinion, may interfere with the in terpretation of QTc interval changes, 
including abnormal ST-T-wave morphology, particularly in the protocol- defined primary 
lead, or left ventricular hypertrophy at Screening or prior to the first study drug 
administration  (out of range test may be repeated once for each visit at the discretion of 
the Investigator) 
12. Prolonged QT interval corrected for HR using Fridericia’s formula (QTcF) >  450 ms  at 
Screenin g or prior to first study drug administration 
13. Shortened QTcF < 340 ms  at Screening or prior to first study drug administration  
14. Family history of long QT syndrome  
15. ECG interval measured from the onset of the P wave to the onset of the QRS complex (PR [PQ]) interval shortening < 120  ms (PR > 110 ms but < 120 ms is acceptable if there 
is no evidence of ventricular preexcitation) at Screening or prior to first study drug administration.  
16. PR (PQ) interval prolongation (>220  ms), persistent or intermittent second (Wenckebach 
block while asleep is not exclusive) or third degree atrioventricular (AV) block, or AV dissociation  at Screening o r prior to first study drug administration .  
17. Persistent or intermittent complete bundle branch block, incomplete bundle branch block, or intraventricular conduction delay with ECG interval measured from the onset of the QRS complex to the J point (QRS) >  110 ms. Subjects with QRS > 110 ms but < 115 ms 
are acceptable if there is no evidence of ventricular hypertrophy or preexcitation  at 
Screening or prior to first study drug administration. 
18. In the predose 24- hour telemetry, presence of  ≥10 ventricular premat ure contractions 
(VPCs) during 1 hour , or ≥ 100 VPCs during 24 hours of telemetry, or any occurrence of 
paired VPC s (ventricular couplets) or other repetitive ventricular rhythms , including non-
sustained or sustained (>  30 second duration), slow  (< 100 bpm), or fast (≥  100 bpm) 
ventricular tachycardias.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 31 of 95 19. Any clinically significant illness in the 28 days prior to the first study drug administration  
20. Heavy smoker (>20 cigarettes per day) and/or is unable to abstain from smoking or 
unable to abstain fr om the use of prohibited nicotine containing products for at least 
1 hour before and at least 6 hours after study drug administration (including e- cigarettes, 
pipes, cigars, chewing tobacco, nicotine topical patches, nicotine gum, or nicotine lozenges) 
21. Regularly consumes excessive amounts of caffeine or xanthines within 30 days prior to 
Screening, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day 
22. History of suicidal ideation within 1 year of Screening (score of 4 or 5 as per the 
C-SSRS) or any suicidal behavior (as per C- SSRS) within 2 years  of Screening, or is 
currently at risk of suicide in the opinion of an Investigator 
23. Positive test result for alcohol and/or drugs of abuse upon admission on Day -2. Subjects with positive marijuana results at admission may be rescheduled at the discretion of an Investigator. If THC is positive at admission, a cannabis intoxication evaluation will be done by an Investigator and subjects may be permitted to continue in the study at the discretion of an Investigator. Other positive test results should be reviewed to determine if the subject may be rescheduled, in the opinion of an Investigator 
24. Positive test results for HIV -1/HIV -2 Antibodies, Hepatitis B surface Antigen (HBsAg) 
or Hepatitis C Virus Antibody (HCVAb) 
25. Any other clinically significant abnormalities in laboratory test results at Screening that 
would, in the opinion of an Investigator , increase the subject's risk of participation, 
jeopardize complete participation in the study, or compromise interpretation of study data 
26. Treatment with an investigational drug within 30 days or 5 times the half- life (whichever 
is longer) prior to S creeni ng 
27. Use of any prescription drugs (with the exception of hormone replacement therapy) in the 14 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy 
28. Use of  St. John’s wort in the 28 days prior to the first study drug administration 
29. Use of over-the-counter (OTC) products (including herbal preparations and supplements) within 7 days prior to the first study drug administration, with the exception of ibuprofen or acetaminophen 
30. Donation of plasma in the 7 days prior to the first study drug administration 
31. Donation of 1 unit of blood to American Red Cross or equivalent organization or donation of over 500 mL of blood in the 56 days prior to the first study drug administration  
32. Is, in the opinion of an Investigator or designee, considered unsuitable or unlikely to comply with the Study Protocol for any reason 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 32 of 95 33. Poor venous access at Screening, as judged by an Investigator 
34. Use of any prescribed or nonprescribed oral and topical inhibitors/inducers of CYP3A4 
(including shampoo) 
35. Is an AZ  or study site employee or their close relatives  
4.3. Rescreening Criteria  
Subjects may be required to be rescreened as part of this study. Subject who are screen failures, 
due to transient exclusion criteria (ie, blood donations, consumption of products within last 28 days, etc), may be rescreened at the discretion of the Investigator, in consultation with the Sponsor.  
A subject within the original screening windo w must meet all eligibility criteria with the 
following conditions:  
• All Day -2 and/or Day - 1 procedures ( Table 6 -1) must be repeated , if already done 
• The subject will retain his/her original subject identification number  
A subject outside of the original screening window must repeat all screening procedures, meet all 
eligibility criteria, and have a new subject identification number is sued.  
4.4. Withdrawal Criteria  
4.4.1. Before First Treatment Administration  
Before the first treatment administration, inclusion/exclusion criteria will govern the subjects to be dosed. If either the urine drug (except for THC) and alcohol screen or the naloxone challenge is positive, the subject will be excluded from the study. Subjects withdrawn before first treatment administration will not be followed up and will not undergo End-of- Study/Early Termination 
assessments. Other safety assessments may be performed if re quired. 
Subjects are free to withdraw their consent to participate in the study at any time, without prejudice. The reason for their withdrawal or for deciding to end their participation will be documented. 
4.4.2. After First Treatment Administration  
Subjects may , at any time, voluntarily withdraw from the study or be removed from the study at 
the discretion of an  Investigator or Sponsor. An  Investigator may withdraw a subject at any time 
for any (but not limited to) of the following reasons: if it is determined that continuing the study 
would result in a significant safety risk to the subject or if their behavior is deleterious to the study environment. If such withdrawal occurs, or if the  subject fails to return for visits, an  
Investigator should determine the primary reason for a subject’s premature withdrawal from the 
study and record the reason in the subject’s study documents.  
In the case of a clinically significant illness detected d uring the trial (including COVID -19 
diagnosis), the Principal Investigator (or delegate) will, in consultation with the Medical Monitor 
and Sponsor P hysician , determine the most appropriate course of action on an individual basis. 
Evaluations will include but are not limited to:  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 33 of 95 • The safety of the subject and other study participants 
• The possible effect the illness would have on the results gathered during the trial, and 
their ability to be appropriately analyzed or interpreted  
• The possibility of suspending participation then re -initiating it after recovery  
• The implication of any inclusion or exclusion criteria that would contradict possible actions  
• The implication of any adherence to regulatory guidelines that may be affected by actions decided; for example group effect analysis  
• The sample size calculation, current number of subjects, and possibility of replacement 
subjects 
Evaluations and decision -making for subject removal will be documented in the study file, 
reported to the Sponsor, and discussed where appropriate in the Clinical Study Report.  
Attempts should be made to have such subjects complete the End of Study/Early T ermination  
assessments. End -of-Study/ ET assessments should be performed as soon as possible after the last 
study treatment administration. 
For subjects lost to follow -up ( ie, those subjects whose status is unclear because they fail to 
appear for study visits without stating an intention to withdraw), an  Investigator should show 
"due diligence" by documenting in the source documents steps taken to contact the subject, 
eg, dates of telephone calls (at least 3), registered letters  (at least 1), etc.  
 Stopping Rules  
4.4.2.1.1. Individual Subject Stopping Rules  
Participation in the clinical study may be discontinued by an Investigator (or delegate) in charge of the study or by the Sponsor for any of the following reasons, but not limited to: 
• AEs (including if a subject develops any significant illness or needs to undergo any major 
surgery during course of the study) 
• Subject non-compliance (including any violation of protocol requirements which may 
affect the study outcome) 
Subjects will be discontinued from the clinical study for any of the following reasons, but not limited to:  
• Total serum bilirubin  > 2x upper limit of normal ( ULN) 
• Aspartate aminotransferase (AST) >  3x ULN  
• Alanine aminotransferase (ALT) > 3x  ULN  
• Creatinine > 1.5x ULN  
4.4.2.1.2. Trial Stopping Rules  
Clinical trial stopping rules:  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 34 of 95 • If 2 AZD4041- related (based on Investigator or Sponsor assessment) SAEs occur  
(Grade  3, 4, or 5) 
• Occurrence of 1 death attributable to the study treat ment \ 
• At least 2 subjects who received AZD4041 have QTc prolongation defined as QTcF > 
500 ms, or a prolongation from baseline of > 60 ms, confirmed (persistent for at least 
5 minutes) and determined postdose either on 12- lead digital ECG  (dECG)  obtained 
during continuous 12-lead ECG monitoring or on a repeat 12- lead safety ECG  
• At least 2 subjects who received AZD4041 have tachycardia defined as resting supine HR > 125 beats per minute persisting for at least 10 minutes  
• At least 2 subjects who received AZD 4041 have symptomatic bradycardia defined as 
resting supine HR < 40 beats per minute or asymptomatic bradycardia defined as resting supine HR < 30 beats per minute while awake persisting for at least 10  minutes 
• At least 2 subjects who received AZD4041 develop hypertension defined as an increase 
in resting supine systolic BP > 40 mmHg and above 180 mmHg and persisting for at least 
10 minutes 
• At least 2 subjects who received AZD4041 develop hypotension defined as an asymptomatic fall in systolic BP > 20 mmHg and below 70 mmHg persisting for at least 
10 minutes, or a symptomatic fall in resting supine systolic BP > 20 mmHg (excluding 
vasovagal reaction or where the Investigator considers this to be most likely related to morphine administration) 
4.5. Lifestyle and/or Dietary R equirements  
• Subjects will be prohibited from consuming food or beverages containing grapefruit and/or pomelo for 7 days prior to the first dosing and during the study. 
• Subjects will be prohibited from consuming alcohol for 48 hours prior the first dosing and during the study. They  will also  be prohibited from recreational drug use from 
screening until the follow -up visit. In case of any doubt, a test for alcohol and/or a drug 
screen may be performed if requested by an Investiga tor. If a subject presents with a 
positive alcohol test or drug screen at any time after the screening visit, the subject may be rescheduled at the discretion of an I nvestigator. If THC is positive at check -in, a 
cannabis intoxication evaluation will be done by an Investigator, and inclusion will be at his or her discretion. 
• Subjects will be prohibited from consuming food or beverages containing xanthines 
(ie, tea, coffee, cola drinks, energy drinks or chocolate) for 48 hours prior to the first 
dosing and during the study. 
• Subjects will eat only the food provided by the study site during confinement at the CRU. 
• During the study, subjects who are smokers should not smoke more than 20 cigarettes  per 
day. Subjects will abstain from smoking for 1 hour prior and until 6 hours after each drug 
administration.  
Protocol No: D7460C00003   
Altasciences Project No: AZN-P1-265  
 
Version 2.0 (Amendment 01), 16-SEP-2022  Page 35 of 95 x Subjects will be asked to refrain from dr iving, operating machinery, or engaging in 
hazardous activities until they and an invest igator are convinced the study drug is not 
impairing their judgment and/or ability to pe rform skilled tasks. 
4.6. Concomitant Treatment 
The naloxone challenge will consist of an initial IV dose of 0.2 mg naloxone HCl. Subjects will 
be observed for signs or symptoms  of opioid withdrawal. If there is no evidence of withdrawal 
within 1 minute (as assessed by a COWS score of  <5), an additional intravenous dose of 0.6 mg 
naloxone HCl will be given, and subjects will be obs erved for signs and symptoms of withdrawal 
for 5 minutes (as assessed by COWS ). Subjects who present sympto ms of withdrawal during the 
qualification process will be excluded from the study and will not be eligible to enter the 
Treatment phase.  
Except for medication which may be required to  treat AEs (eg, paracetamol/acetaminophen), no 
other treatment or medication other than the st udy drugs will be allowed from the first dosing 
until all study activities and evaluations have been completed.  
Subjects will be instructed to notify the study si te about any new medica tions (eg, those required 
to treat AEs) taken after the st art of the study treatment. All me dications and significant non-drug 
therapies (including physical ther apy and blood transfusions) admin istered after th e subject has 
received the study treatment must be listed in  the subject CRF. The drug name and dose taken 
will be noted. An investigator or delegate and/or  the Sponsor will decide whether the subject will 
be permitted to remain in the study, depending on  the drug used, the time  of drug intake, etc. 
5. STUDY TREATMENTS 
5.1. Investigational Products 
The active IP will be provided by the Sponsor . The placebo will be provided by the CRU. 
5.1.1.  AZD4041  and Placebo oral solution 
The AZD4041 active formulation and placebo are presented in Table 5-1 . CCI
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 37 of 95 Subjects who sign the ICF and are randomized but do not receive the study treatment may be 
replaced. Subjects who sign the ICF are randomized and receive the study treatment, and 
subsequently withdraw, or are withdrawn or discontinued from the study, will generally not be 
replaced. However, consideration may be given to the replacement of such subjects in order to enable the completion of at least 36 subjects (n=24 randomized to Sequence 1 and n=12 randomized to S equence 2) to ensure that  the scientific integrity of the study is maintained . 
Replacement of subjects will be at the discretion of the Principal Investigator in consulta tion and 
agreement with the Medical Monitor and Sponsor Physician. Any decision to replace subjects should not conflict with the pre-defined individual subject or study stopping rules, or otherwise jeopardise the safe conduct of the study.  
5.2.4. Blinding  
The ran domization code will not be available to the personnel of the bioanalytical facility until 
the bioanalytical phase of the study has been completed. The treatment assignment will not be known by the study participants. 
Furthermore, the randomization code wi ll not be available to the physician and clinical staff 
involved in the collection, monitoring, revision, or evaluation of AEs, as well as clinical staff 
who could have an impact on the outcome of the study, and including the pharmacokineticist (or 
delegate , until all the case report forms  (CRFs)  have been approved and signed and the 
bioanalytical phase of the study has been completed. 
The preparation and/or administration of the products will be done by designated personnel that 
are not directly involved in the clinical aspects of the trial.  
The randomization code must not be broken except in emergency situations where the identification of a subject’s study treatment is required by an  Investigator for further treatment to 
the subject or to complete a SAE  report. Randomization information will be held by designated 
individual(s). The date and reason for breaking the blind must be recorded. 
5.2.5. Study Drug Accountability  
Complete and accurate inventory records of all study drugs will be maintained . This includes 
acknowledgment of receipt of each shipment of study product (quantity and condition), subject 
dispensing records, and returned or destroyed study product.  
The labeling, storage conditions, quantity of reserve samples for the IP , and retention period of 
the reserve samples shall comply with the current Food and Drug Administration (FDA) rules 
and regulations . Drug accountability will be performed at the completion of the trial.  
5.3. Administration of Study Drug  
Study treatments as described in Section 3.2 will be administered in the morning. The date and time of each dose will be recorded. For each subject, Day 1 to Day 14 scheduled postdose activities and assessments will be performed relative to the time  of AZD4041/placebo 
administration or end of morphine infusion. From Day 15, all scheduled postdose activities will be performed relative to the end of morphine infusion, with the exception of PK sampling for AZD4041. 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 38 of 95 On Day 1, a single intravenous infusion of morphine will be administered to the subjects  over a 
10-minute  interval (± 30 seconds)  in the morning . 
On Days  2 to 15, an oral dose of the assigned treatment (either AZD4041 or Placebo) once daily 
will be administered to subjects  using a syringe for 1 4 consecutive days . The dose will be 
administered directly into the subject’s mouth.  
On the morning of Day 15, the oral dose of the assigned treatment (either AZD4041 or Placebo) 
will be combined with a single intravenous infusion of morphine. A single intravenous infusion of morphine will be administered to the subjects over a 10-minute interval (± 30 seconds). The assigned tre atment  (AZD4041 or Placebo) will then be administered orally immediately (within 
1 minute) after the end of morphine infusion. 
The s tudy drugs will be dispensed only to eligible subjects and administered under the 
supervision of study personnel. Treatment compliance will be verified according to the site’s standard operating procedures ( SOPs ). 
5.4. Meals  
Food intake will be controlled for the  confinement period and for all subjects. 
Subjects will be required to fast at least 10 hours prior to start of morphine infusion on Days  1 to 15. 
On Days 1, 8, and 15, s ubjects will also be required to fast (abstain from food) for at least 
4 hours after dosing (after end of morphine infusion on Day 15). 
5.5. Fluids  
Fluid intake other than water will be controlled for each confinement period and for all subjects. 
On Days 1, 8, and 15, w ater will be permitted  as needed except from at least 1 hour predose  
(prior to start of morphine infusion on Days 1 and 15) until 1 hour after dosing (after end of 
morphine infusion on Days 1 and 15). 
No water restriction will be implemented for the study drug administrations on Days  2 to 7, and 
Days 9 to 14. 5.6. Other Protocol Restrictions  
On Days  1, 8 and 15, subjects will remain seated or kept in minimal ambulatory movement for 
the first 4  hours following study drug administration (after end of morphine infusion on Days 1 
and 15), avoiding both vigorous exertion and complete rest. On Days  2 to 7, and Days 9 to 14, 
subjects will remain seated or kept in minimal ambulatory movement for the first hour following 
study drug administration, avoiding both vigorous exertion and complete rest. However, should AEs occur at any time, subjects may be placed in an appropriate position. During these intervals, subjects will be perm itted, under supervision, to get up (eg, to use the washroom facilities). 
Subjects will not engage in strenuous activity at any time during the confinement period. 
6. STUDY PROCEDURE S 
An overview of the study activities for each participant is detailed in Table 6 -1. 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 39 of 95 Unless otherwise stated in the protocol, the SOPs of the study facilities, which are available for 
all activities relevant to the quality of the study, will be followed during this study. When the 
nominal time for multiple events occurs simultaneously, the events will be staggered using their acceptable windows (acceptable windows for each assessment are specified in the following sections of this protocol), with priority given to those events related to primary study endpoints. Safety procedures will be carried out in the following order if scheduled at the same time: ECG recording> vital sign assessments, respiratory rate , SpO
2, EtC O2> dECG extraction>  PK 
sampling. 
Any deviation from protocol procedures should be noted in the source documentation and 
compiled for reporting in the Clinical Study Report.  
 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 44 of 95 6.1. Safety  Assessments  
Safety assessments will include physical examination, neurological examination, vital signs 
(systolic and diastolic BP, HR, and oral temperature), 12- lead safety ECGs, 12- lead dECGs, 
ECG telemetry , C-SSRS questionnaires, clinical laboratory tests, EtCO 2, SpO 2, respiratory rate , 
and AE monitoring. At the discretion of an Investigator, additional safety assessments may be 
performed as needed to ensure subject safety.  
6.1.1. Medical History  
The medical history at Screening will include all queries by the medical and clinical staff related 
to the subject’s  well -being and history of relevant  past medical events/experiences.  Medical 
history will include all d emographic data (age, sex , race, body weight, height, and BMI) and 
baseline characteristics.  Alcohol and smoking habits will also be recorded. 
6.1.2. Recreational Alcohol/Drug Use 
A lifetime history of all drug use, including alcohol, will be collected as scheduled in Table 6 -1. 
For drug use (except alcohol), history, including drug preference (ie, drug of choice), frequency 
of use, and date of last use will be collected using reported drug names and drug class (eg, 
cannabinoids, depressants, dissociative anesthetics, hallucinogens, opioids and morphine derivatives, and stimulants). DSM -5 modules will be included as a part of the recreational 
drug/alcohol use history and used to screen for alcohol and substance use disorder . 
6.1.3. Physical Examination  
A physical examination will be performed by a medically qualified and licensed individual a s 
outlined  in Table 6 -1. 
The physical examination will include a general review  of the  following  body systems (at 
minimum): head and neck, cardiovascular , respiratory , gastrointestinal, brief neurological ( if a 
full neurological examination  is not scheduled), and general appearance, unless a symptom-
oriented physical exam is indicated.  
A Sponsor- provided form will be used to fa cilitate a standardized approach to the physical 
examination (APPENDIX 11 ). 
6.1.4. Neurological Examination  
Neurological examination  (assessments of basic mental status, cranial nerves, motor function, 
reflexes, sensation, proprioception, coordination, and gait) will be perf ormed as scheduled in  
Table 6 -1. 
A Sponsor- provided form will be used to facilitate a standardized approach to the physical 
examination (APPENDIX 12 ). 
6.1.5. Vital Signs  
Vital signs will be measured as outlined in Table 6 -1 and specifically in Table 6 -2.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 45 of 95 Table 6-2  Vital Sign Recording Schedule  
Vital Sign Recording - Scheduled Timepoints  
Screening  
Day -2 
Days 1: predose and 1, 2, 3, 4, 6, 8, and 12 hours postdose  
Days 2 to 14: predose, and 1 hour postdose 
Day 15: predose and 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours postdose  
Follow -up visit /ET 
Abbreviations:  ET = Early Termination  
Vital signs will include BP, HR, and oral temperature  (at Screening, Day -2, discharge, and 
Follow-up visit/ Early Termination only).   
Vital signs will be taken while subjects are rested and supine for at least 5 minutes.  
The acceptable windows for vital sign assessments are presented in  Table  6-3. 
Table  6-3 Acceptable Windows for Vital Sign Assessments Procedures 
Elapsed Time  Accepted Window 
Predose within 60 minutes  
> 0 hour and ≤ 24 hours  ± 30 minutes  
> 24 hours and ≤ 72 hours  ± 60 minutes  
 
6.1.6. 12-Lead Electrocardiogram  
 12-Lead  Safety  Electrocardiogram  
The 12- lead safety ECGs will be performed as outlined in Table 6 -1 and specifically in 
Table  6-4. Additional safety ECGs may be performed at the Investigator’s discretion. The 
12-lead ECGs will be obtained after the subject has been resting in the supine position for at least 
10 minutes. All 12 -lead ECGs will be evaluated for HR, and for PR, time elapsed between two 
successive R -waves of the QRS signal on the ECG (RR), QRS, QT, and QTcF intervals, and the 
Investigator will judge the overall interpretation as normal or abnormal. If abnormal, it will be decided whether or not the abnormality is clinically significant or not clinically significant, and the reason for the abnormality will be recorded. The date/time, physician interpretation (normal, abnormal clinically significant, abnormal no t clinically significant), and all evaluated parameters 
and intervals will be recorded in the electronic CRF (eCRF), and the paper printouts will be stored at the site. The Investigator (or designee) will evaluate the printout of the 12 -lead ECG in 
real ti me, and with particular attention to the effects of clinical importance on the PR, QRS, and 
QTcF intervals.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 46 of 95 Table  6-4 Safety ECG Recording Schedule  
Safety ECG Recording - Scheduled Timepointsa  
Screening  
Day -2 
Days 1b: predose and 1, 2, 4, 6 , and 12 hours postdose  
Days 2 to 14b: predose and 1 hour postdose  
Day 15b: predose and 1, 2, 4, 6, 12, 24, 48, and 72 hours postdose  
Follow -up visit /ET 
Abbreviations: ET  = Early Termination  
a. Safety procedures will be carried out in the following order: ECG recording>Vital sign assessments>PK sampling  
b. Predose safety ECG s should be recorded within 60 minutes of the scheduled dosing time and BEFORE vital sign 
assessments and PK sampling.  
 
The acceptable windows for 12- lead safety ECG assessments are presented in Table  6-5. 
Table  6-5 Acceptable Windows for 12 -Lead Safety Electrocardiogram Assessments 
Procedures  
Elapsed Time  Accepted Window 
Predose within 60 minutes  
> 0 hour and ≤ 24 hours  ± 30 minutes  
> 24 hours and ≤ 72 hours  ± 60 minutes  
 Electronic Capture of 12 -lead Continuous Digital Electrocardiogram 
The AZ ECG Center will perform the  dECG analysis, using the  EClysis© system, version  4.0, or 
higher. Lead V2 will be used as the primary analysis lead, with lead V5 as the primary backup 
lead and lead II as the secondary back-up lead, for all time points when lead V2 is found to be 
unsuitable for analysis. 
At clinical study protocol -indicated time points in Table 6 -6, 12 -lead continuous  dECG files will 
be recorded using the 12- lead Mortara Holter equipment (H12+) according to  AZ ECG Center’s 
standard procedures for settings/configuration, recording and transfer of dECGs.  The 12- lead 
Holter memory cards will be sent to the AZ ECG Center with an agreed courier.  
It is to be noted that the 12-lead Holter recordings will serve multiple purposes. It will be the source 
for 12-lead dECG extractions. In addition to providing 12-lead dECG extractions, the recordings will 
be used for prolonged arrhythmia monitoring as part of the safety data collection (these data will be 
analy zed at a later stage and will not be available for the bedside safety monitoring at site).  The 
first ECG recording with Holter device  starts on  Day -1 (approximately  24 hours before dosing) 
and continues to 72 hours postdose (Day 4). On Day 8, recording will start at least 1 hour before 
dosing and continue to 24 h ours postdose. On Day 15, recording will start at least 1 hour before 
dosing and continue to 72 hours postdose (Day 18). Specific extraction times for dECG are 
presented in Table 6 -6. 
The same recording device will be used for each subject at all time points, when possible. Date and time settings must be checked on the Mortara Holter equipment, at the start of each study 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 47 of 95 day and aligned with an official timekeeper.  The metadata of each file will be checked by the 
responsible personnel at the study site to ensure that the cards sent to the AZ central  dECG  files 
repository have correct metadata.  
Skin preparation must be thorough and electrode positions must be according to standard 12- lead 
ECG placement. Permanent electrodes will be applied at least 30 minutes before first study 
recording and left in place for the duration of each relevant study day. Elect rode positions 
for dECG take precedence over those for telemetry.  Subjects will rest in a supine position for at 
least 5 to 10 minutes before the start of each recording. A shorter resting period (at least 5 minutes) may be done in certain cases, depending  on competing procedures in the study.  
The subject should be in the same supine body position (maximum 30 degrees flexion of the hip and feet not in contact with the footboard) at each recording time point during the study.  
From the continuous  dECG  files received at the AZ ECG Centre, the  EClysis
© system will 
extract continuous files of at least 5 minutes length at clinical study protocol- indicated time 
points in Table 6 -6. The extraction window can be adjusted by the responsible ECG Scientific 
Advisor during the Metadata approval procedure, based on the ‘Clinical Logs’ received from the site. As standard, from each  dECG extracted window, 10-second ECGs will then be extracted by  
the EClysis
© system twice per minute and automatically analyzed by the software. The ECG 
Scientific Advisor will perform all necessary manual corrections of the ECG annotations provided automatically by EClysis
©. All dECGs  from 1 subject will be  analy zed by a single 
reader in a blinded manner.  
The AZ ECG Centre Cardiologist will finally review all data and perform all necessary adjustments before locking the data into a read-only state. From the locked data, the nume rical 
values for the ECG intervals and amplitudes will then be made accessible on a secure file share of the AZ dECG central repository to accredited Data Management specialists for conversion into SAS
® files.  
The following dECG variables will be reported by the AZ ECG Centre: RR, PR, QRS , and QT 
intervals from the lead , defined as the primary analysis lead, as well as potential T -wave 
morphology changes. 
Derived parameters (QTcF, HR, and others, as applicable) are calculated by the study statistician 
or de legate.  
Table 6-6 Digital Electrocardiogram Schedule  
Study 
Day Visit 
Number  ECG 
Number  Time:  
Start of the 
Extraction 
Window,  
Hour:Mina,b Dose Time:  
Stop of the 
Extraction 
Window,  
Hour:Min  dECG  
Continuous c, d, e Otherf 
1 2  -02:00   -01:30   Apply electrodes  
1 2  -01:10   -01:00   Rest in bed d 
1 2 1 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min   
1 2  00:00  IP 
administration     
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 48 of 95 Study 
Day Visit 
Number  ECG 
Number  Time:  
Start of the 
Extraction 
Window,  
Hour:Mina,b Dose Time:  
Stop of the 
Extraction 
Window,  
Hour:Min  dECG  
Continuous c, d, e Otherf 
1 2 2 00:25   00:30  5 min   
1 2 3 00:55   01:00  5 min   
1 2 4 01:55   02:00  5 min   
1 2 5 03:55   04:00  5 min   
1 2 6 05:55   06:00  5 min   
1 2 7 07:55   08:00  5 min   
1 2 8 11:55   12:00  5 min   
2 2  -02:00   -01:30   Apply electrodes  
2 2  -01:10   -01:00   Rest in bed d 
2 2 9 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 2 
2 2  00:00  IP 
administration     
2 2 10 00:25   00:30  5 min   
2 2 11 00:55   01:00  5 min   
2 2 12 01:55   02:00  5 min   
2 2 13 03:55   04:00  5 min  
2 2 14 05:55   06:00  5 min   
2 2 15 07:55   08:00  5 min   
2 2 16 11:55  12:00 5 min   
3 2  -02:00   -01:30   Apply electrodes  
3 2  -01:10   -01:00   Rest in bed d 
3 2 17 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 3 
3 2  00:00  IP 
administration     
3 2 18 03:55   04:00  5 min   
3 2 19 11:55   12:00  5 min   
4 2  -02:00   -01:30   Apply electrodes  
4 2  -01:10   -01:00   Rest in bed d 
4 2 20 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 4 
4 2  00:00  IP 
administration     
4 2 21 03:55   04:00 5 min   
5 2  -02:00   -01:30   Apply electrodes  
5 2  -01:10   -01:00   Rest in bed d 
5 2 22 -01:00 (within 60 
min prior to Predose  -00:50  10 min  Predose Day 5 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 49 of 95 Study 
Day Visit 
Number  ECG 
Number  Time:  
Start of the 
Extraction 
Window,  
Hour:Mina,b Dose Time:  
Stop of the 
Extraction 
Window,  
Hour:Min  dECG  
Continuous c, d, e Otherf 
dosing)  
5 2  00:00  IP 
administration     
5 2 23 3:55  04:00  5 min   
6 2  -02:00   -01:30   Apply electrodes  
6 2  -01:10   -01:00   Rest in bed d 
6 2 24 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 6 
6 2  00:00  IP 
administration     
7 2  -02:00   -01:30   Apply electrodes  
7 2  -01:10   -01:00   Rest in bed d 
7 2 25 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 7 
7 2  00:00  IP 
administration     
8 2  -02:00  
  -01:30  
  Apply electrodes  
8 2  -01:10  
  -01:00  
  Rest in bed d 
8 2 26 -01:00 (within 
60 min prior to 
dosing)  
 Predose  
 -00:50  
 10 min  
 Predose Day 8 
8 2  00:00  IP 
administration     
8 2 27 00:55   01:00  5 min   
8 2 28 03:55   04:00  5 min   
 
8 2 29 05:55   06:00  5 min   
8 2 30 07:55   08:00  5 min   
8 2 31 11:55   12:00  5 min   
9 2  -02:00   -01:30   Apply electrodes  
9 2  -01:10   -01:00   Rest in bed d 
9 2 32 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 9 
9 2  00:00  IP 
administration     
10 2  -02:00   -01:30   Apply electrodes  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 50 of 95 Study 
Day Visit 
Number  ECG 
Number  Time:  
Start of the 
Extraction 
Window,  
Hour:Mina,b Dose Time:  
Stop of the 
Extraction 
Window,  
Hour:Min  dECG  
Continuous c, d, e Otherf 
10 2  -01:10   -01:00   Rest in bed d 
10 2 33 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 10 
10 2  00:00  IP 
administration     
11 2  -02:00   -01:30   Apply electrodes  
11 2  -01:10   -01:00   Rest in bed d 
11 2 34 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 11 
11 2  00:00  IP 
administration     
11 2 35 03:55   04:00  5 min   
12 2  -02:00   -01:30   Apply electrodes  
12 2  -01:10   -01:00   Rest in bed d 
12 2 36 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min Predose Day 12 
12 2  00:00  IP 
administration     
13 2  -02:00   -01:30   Apply electrodes  
13 2  -01:10   -01:00   Rest in bed d 
13 2 37 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 13 
13 2  00:00  IP 
administration     
13 2 38 03:55   04:00  5 min   
14 2  -02:00   -01:30   Apply electrodes  
14 2  -01:10   -01:00   Rest in bed d 
14 2 39 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 14 
14 2  00:00  IP 
administration     
15 2  -02:00   -01:30   Apply electrodes  
15 2  -01:10   -01:00   Rest in bed d 
15 2 40 -01:00 (within 
60 min prior to 
dosing)  Predose  -00:50  10 min  Predose Day 15 
15 2  00:00  IP    
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 51 of 95 Study 
Day Visit 
Number  ECG 
Number  Time:  
Start of the 
Extraction 
Window,  
Hour:Mina,b Dose Time:  
Stop of the 
Extraction 
Window,  
Hour:Min  dECG  
Continuous c, d, e Otherf 
administration  
15 2 41 00:25   00:30  5 min   
15 2 42 00:55   01:00  5 min   
15 2 43 01:55   02:00  5 min   
15 2 44 03:55   04:00  5 min   
15 2 45 05:55   06:00  5 min   
15 2 46 07:55   08:00  5 min   
15 2 47 11:55   12:00  5 min   
16 2 48 23:55   24:00  5 min   
16 2 49 35:55   36:00  5 min   
17 2 50 47:55   48:00  5 min   
18 2 51 71:55   72:00  5 min   
a. Time points for dECG may be adjusted according to emerging PK data.  
b. Subjects must be in the same supine body position (maximum 30 degrees flexion in the hip) at each time point 
and at all visits with feet out of contact with footboard.  
c. Skin must be cleaned and electrode positions marked with an indelible pen. Electrodes should be applied at least 
30 minutes  before the first recording.  
d. The subjects must rest in bed  (supine position)  for at least 10 min utes prior to each dECG time point.  A shorter 
resting period (at least 5 minutes) may be done in certain cases, depending on competing procedures in the study.  
e. The subject must remain awake.  
f. In some cases (when continuous monitoring is being performed), re -application of electrodes would not always 
be necessary. Electrodes are checked for contact and replaced if needed.  
Abbreviations: dECG  = digital electrocardiogram, ECG  = electrocardiogram; IP  = investigational product; 
min = minute; PK: p harmacokinetic.  
Note: On Day 1 and Day 15, predose time points are relative to start of morphine infusion and postdose time points 
are relative to end of morphine infusion.  
Table 6-7 Window Allowance for dECG time points  
Procedure  Time Point  Tolerance 
Window  Notes  
Days 1  Predose  - 60 min to 0 h  Within max 1h predose. Start of dECG Extraction 
time window should occur at 5 -7 min prior to 
nominal PK sampling timepoint. Subject should 
have been awake for at least 1h prior to dECG 
baseline in studies where ECG/QT are important  
Days 2 -15 Predose  - 60 min to 0 h  Within max 1h pred ose. Start of dECG Extraction 
time window should occur at 5 -7 min prior to 
nominal PK sampling timepoint. N.B. dECG 
should always be sampled immediately before 
supine vital PK draw.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 52 of 95 Procedure  Time Point  Tolerance 
Window  Notes  
Days 1 -15 Up to 12 h postdose  - 15 to + 15 min  Start of dECG Extraction time window should 
occur at 5 -7 min prior to nominal PK sampling 
timepoint ±15 min. N.B. dECG should always be 
sampled immediately before supine vital PK draw  
Day 2  24 h postdose  - 60 to + 60 min  Start of dECG Extraction time window should 
occur at 5 -7 min prior to nominal PK sampling 
timepoint ±60 min. N.B. dECG should always be 
sampled immediately before supine vital PK draw  
Day 16  24 and 36h postdose  - 60 to + 60 min  Start of dECG Extraction time window should 
occur at 5 -7 min pri or to nominal PK sampling 
timepoint ±60 min. N.B. dECG should always be 
sampled immediately before supine vital PK draw  
Days 17 and 18  48 and 72h postdose    
- 2h to + 2h 
  Start of dECG Extraction time window should 
occur at 5 -7 min prior to nominal PK sampling 
timepoint ±2h. N.B. dECG should always be 
sampled immediately before supine vital PK draw  
Notes:  
Start  of dECG Extraction time window should occur at 5 -7 min prior to nominal PK sampling time point. ECG 
needs to be closely coordinated  with PK in ECG critical studies to maintain precision for analysis, or modelling, so 
the deviation from nominal time tolerance window for PK sets the frame also for dECG   
N.B. dECG should always be sampled immediately before supine vitals, followed by PK blood draw. Other, less 
rest dependent pharmacodynamic measurements follow immediately after the PK draw   
The tolerances for dECG reporting in this document represent those  used in the clinic when ensuring the subject is 
prepared for the start of dECG Extraction time window.  
Time window deviations for actual dECG results will be calculated and provided by the AstraZeneca ECG center 
during analysis as these will relate to the time of extraction of each ECG. This information will not be available in 
the study database.  
6.1.7. ECG Telemetry  
Subjects will be monitored by telemetry  as outlined in Table 6 -1. To allow a real -time 
assessment of cardiac safety ( HR, rhythm, and ECG morphology) at the CRU, subjects will be 
monitored at least by 2- lead telemetry. Telemetry monitoring will be performed on Day -1 
(starting approximately 24 hours before the start of morphine IV infusion) until 72 hours after 
the end of morphine IV infusion (Day 4), on Day 7 at least 30 minutes prior to AZD4041 or placebo dosing until 48 hours post Day 7 dose (Day 9), and on Day 15 at least 30 minutes before the start of morphine IV infusion  and until 72 hours after the end of morphine IV infusion 
(Day  18). Any clinically significant change noted on telemetry will be followed up with a 
12‑lead safety ECG. Further evaluation including any treatment will be performed as deemed appropriate by the Investigator. Any finding of short, self- limiting, asymptomatic arrhythmia (eg, 
non‑significant supraventricular tachycardia, atrial fibrillation or flutter, ventricular 
extrasystoles, ventricular tachycardia), should be documented and further evaluated in the context of the individual subject’s history and clinical status. Irrespective of the intervention, 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 53 of 95 cardiac monitoring will be continued until an observed event resolves or the subject is deemed 
clinically stable by the Investigator.  
6.1.8. Continuous and Spot Oxygen Saturation  
Assessments will include continuous and spot SpO 2 monitoring, as scheduled in Table 6 -1. 
Continuous and spot SpO 2 will be monitored using a capnography monitor except for the spot 
SpO 2 at Screening , Day -2, and Follow-up visit/ ET which will use a portable pulse oximeter 
placed on the subjects’ fingertip. SpO 2 will be continuously monitored for alarms from at least  
1 hour prior to each study drug administration (prior to start of morphine IV infusion on Day 1 
and Day 15) and will continue for up to 6 hours following each study drug administration  (after 
the end of morphine IV infusion on Day 1 and Day 15) , or longer if deemed medically necessary . 
Spot SpO 2 will be documented as scheduled in Table  6-8. Baseline SpO 2 will be determined at 
6 timepoints predose on Day 1. The baseline value will be determined by averaging the 6 readings.  
Table  6-8 Spot Oxygen Saturation Recording Schedule  
Spot Oxygen Saturation  Recording - Scheduled Timepoints  
Screening  
Day -2 
Day 1: predose ( at -60, -50, -40, -30, -20, and -10 minutes ) and 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8 , 
and 12 postdose  
Days 2 to 7: predose  
Day 8: predose and 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose  
Days 9 to 14: predose   
Day 15: predose and  15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose  
Follow -up visit/ET 
Abbreviation: ET  = Early Termination  
Note: On Day 1 and Day 15, predose time points are relative to start of morphine infusion and postdose time points 
are relative to end of morphine infusion.  
The acceptable windows for spot SpO 2 recording are presented in Table  6-9. 
Table  6-9 Acceptable Windows f or SpO 2 Assessments Procedures  
Elapsed Time  Accepted Window 
≥ -1 hour and <  1 hour  ± 10 minutes  
≥ 1 hour and ≤ 24 hours  ± 30 minutes  
6.1.9. Continuous and Spot End- Tidal Carbon Dioxide 
End-tidal carbon dioxide  (EtCO 2) will be monitored and measured using a standardi zed 
methodology and configuration using MICROSREAMTM consumables to sample gas via nasal 
cannulae and the CAPNOSTREAMTM20P bedside monitor according to Altasciences SOP  on 
Capnography (CLS-5105-00, September 1st 2020). Using this configuration, for the 
spontaneously breathing healthy volunteer subject, baseline EtCO 2 measurements can be 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 54 of 95 expected to fall within the  range 34-48 mmHg . Measurement of EtCO 2 has been applied 
successfully  in the setting of clinical pharmacology studies for the evaluation of respiratory 
function ( Viscusi et al, 2021). Historical data sets generated at the Altasciences clinical unit h ave 
recorded EtCO 2 values with acceptab le variability in relatively small cohorts of healthy volunteer 
subjects. For example, in a cohort of N=8 subjects, mean baseline EtCO 2 was found to be 36.6 
mmHg  with SD 2.2 mmHg. In another cohort of N=15 subjects, mean baseline EtCO 2 was found 
to be 36.1 mmHg with SD 3.88 mmHg.  
Assessments will include continuous and spot EtCO 2 through a capnography monitor, as 
scheduled in Table 6 -1. EtCO 2 will be monitored continuously for alarms at least  1 hour prior to 
each study drug administration (prior to start of morphine IV infusion on Day 1 and Day 15) and 
will continue for up to 6 hours following each study drug administration  (after the end of 
morphine IV infusion on Day 1 and Day 15), or longer if deemed medically necessary. Spot EtCO
2 will be recorded as scheduled in Table 6 -10. Baseline EtCO 2 will be determined at 6 time  
points predose on Day 1. The baseline value will be determined by averaging the 6 readings.  
Table 6-10 Spot End- Tidal CO 2 Recording Schedule  
Spot End -Tidal CO 2 Recording - Scheduled Timepoints  
Day 1: predose ( at -60, -50, -40, -30, -20, and -10 minutes ) and 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8 
and 12 postdose  
Days 2 to 7: predose  
Day 8: predose and 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8 and 12  hours postdose  
Days 9 to 14: predose  
Day 15: predose and  15, 30 minutes and 1,  1.5, 2, 3, 4, 6, 8, 12 and 24 hours postdose  
Note: On Day 1 and Day 15, predose time points are relative to start of morphine infusion and postdose time points 
are relative to end of morphine infusion.  
The acceptable windows for EtCO 2 assessments are presented in Table  6-11. 
Table  6-11 Acceptable Windows for EtCO 2 Assessments Procedures  
Elapsed Time  Accepted Window 
≥ -1 hour and <  1 hour  ± 10 minutes  
≥ 1 hour and ≤ 24 hours  ± 30 minutes  
 
6.1.10. Continuous and Spot Respiratory Rate  
Assessments will include continuous and spot respiratory rate as scheduled in Table 6 -1. 
Continuous and spot respiratory rate will be monitored /measured  using a capnography monitor 
except at Screening , Day -2, and Follow-up visit/ET where it will be measured by counting the 
number of breaths per minute . Respiratory rate will be continuously monitored for alarms from 
at least  1 hour prior to each study drug administration (prior to start of morphine IV infusion on 
Day 1 and Day 15) and will continue for up to 6 hours following each study drug administration  
(after the end of morphine IV infusion on Day 1 and Day 15), or longer if deemed medically 
necessary. Spot respiratory rate will be measured as scheduled in Table 6 -12. Baseline 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 55 of 95 respiratory rate will be determined at  6 timepoints predose on Day 1. The baseline value will be 
determined by averaging the 6 readings.  
Table 6-12 Spot Respiratory Rate Recording Schedule 
Spot Respiratory rate Recording - Scheduled Timepoints  
Screening  
Day -2 
Day 1: predose ( at -60, -50, -40, -30, -20, and -10 minutes) and 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8 
and 12 postdose  
Days 2 to 7: predose  
Day 8: predose (within 60 minutes) and 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8 and 12  hours postdose  
Days 9 to 14: predose  
Day 15: predose (within 60 minutes) and15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 ho urs 
postdose  
Follow -up visit/ET 
Abbreviation: ET  = Early Termination  
Note: On Day 1 and Day 15, predose time points are relative to start of morphine infusion and postdose time points 
are relative to end of morphine infusion.  
The acceptable windows for respiratory rate assessments are presented in Table  6-11.  
Table  6-13 Acceptable Windows for Respiratory Rate Assessments Procedures  
Elapsed Time  Accepted Window 
≥ -1 hour and <  1 hour  ± 10 minutes  
≥ 1 hour and ≤ 24 hours  ± 30 minutes  
 
6.1.11. Laboratory Evaluations 
Laboratory evaluations will be performed as outlined in  Table 6 -1. 
The laboratory evaluations to be conducted for this study are presented in APPENDIX 6 . 
Additional clinical laboratory tests may be performed by the medical laboratory as part of larger 
standard test panels (not required for subject safety).  
The Investigator or delegate will assess each abnormal value to determine if it is clinically 
significant. Postdose clinically significant laboratory values will be reported as AEs, if 
applicable, as judged by the Investigator or delegate.  
Only test results required by the P rotocol and/or abnorm al results will be entered in the clinical 
database and reported in the Clinical Study Report, based on report requirement. 
6.1.12. Columbia Suicide Severity Rating Scale (C -SSRS)  
The C -SSRS is a questionnaire designed for the assessment of suicidal ideation and b ehaviour in 
adolescents and adults.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 56 of 95 The C -SSRS will assess suicidality over the month preceding Screening as well as over the 
subject’s lifetime. At Screening, the “Baseline /Screening ” version of the scale will be used, and 
at subsequent visits the “Since Last Visit” version of the scale will be used. Versions of the 
instrument relevant to the subject’s native language (ie, English) should be used. C- SSRS 
evaluations will be undertaken at the timepoints indicated in Table 6 -1. 
The questionnaire must be administered by an Investigator or other individual that is suitably 
qualified by education or training. See APPENDIX 7  for a sample C -SSRS –Baseline/Screening  
version assessment and APPENDIX 8  for a sample C -SSRS- Since Last Visit version assessment.  
If there is a positiv e result for suicidality on the C -SSRS after Screening (defined by a subject 
answering “yes’ to questions 4 or 5 on the suicidal ideation portion of the C-SSRS), the subject will be evaluated by an Investigator or medically  qualified Sub- investigator for c ontinuation in 
the study. 
If a subject becomes suicidal during the study, an Investigator should provide the appropriate 
treatment to the subject.  
6.1.13. Clinical Opioid Withdrawal Scale ( COWS ) 
The n aloxone HCl challenge will be conducted as indicated in Table  6-1 for eligible  subjects. 
Clinical Opioid Withdrawal Scale is a clinician -administered, pen and paper instrument that rates 
11 common opiate withdrawal signs or symptoms. The summed score of the eleven items can be used to assess a subject’s level of opiate withdrawal and to make inferences about their level of physical dependence on opioids ( Wesson and Ling, 2003). The scale must be administered by an 
Investigator or other individual that is suitably qualified by education or training. See APPENDIX 9  for a sample of COW S. 
6.1.14. Assessment of Respiratory Depression  
Capnography alarms will be set to evaluate for respiratory depression and will include: 
• An increase in EtCO
2 of at least 10 mmHg compared to baseline or >50 mmHg, 
whichever value is the lowest  
• A reduction in O 2 saturation to <92% 
• A reduction in respiratory rate to <6 breaths per minute  
All alarms will be assessed for clinical significance and reported as AEs, as applicable. Supplemental oxygen will be given as medically necessary.  Events will be timed using a 
stopwatch or equivalent to confirm clinical relevance. Interventions used to treat respiratory 
depression will be documented. 
6.1.15. Medical Interventions for Signs of Respiratory Depression  
In the event that subjects show signs and symptoms of respiratory depression, the Investigator or 
study staff will begin intervention procedures that may escalate in the degree of intervention as follows:  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 57 of 95 • Verbal stimuli: Call the subject’s name loudly. If no response and/or no improvement in 
respiratory depression, proceed to phy sical stimuli.  
• Physical stimuli: Apply sternal rub to subject and/or apply nail bed pressure. If subject is unable to be aroused and/or there is no improvement in signs of respiratory depression, proceed to O
2 administration and prepare for possible naloxone administration (if there is 
no improvement with verbal or physical stimuli, there is a high likelihood of requiring naloxone administration).  
• O
2 administration: Administer oxygen with a target SpO 2 of 95 -100%. Prepare naloxone 
for administration if no i mprovement in respiratory depression clinical parameters or as 
per Investigator discretion.  
• Naloxone administration: Administer naloxone (eg, 4 mg/spray IN every 2- 3 minutes; 0.4 
mg IV every 2 -3 minutes to a maximum of 10 mg) and titrate until adequate 
oxygenation/ventilation is achieved.  
The Investigator or designee will choose the appropriate level of intervention as deemed medically necessary. Subjects who receive intervention will be evaluated to determine if further intervention (eg, hospitalization) i s warranted. Subjects who show significant signs of respiratory 
depression that requires naloxone administration or poses significant safety concerns may be withdrawn from the study at the discretion of the Investigator or designee.  
6.1.16. Rescue Therapy  
The clinical study site is equipped with emergency equipment and supplies that correspond with the level of risk associated with this study. In case of a medical emergency or an SAE requiring medical intervention, emergency equipment and supplies will be a vailable and will include, but 
may not be limited to, stocked crash carts, oxygen source, suction pump, and defibrillator. Emergency medication (eg, naloxone ) or rescue medication required for advanced cardiac life 
support may be administered if deemed necessary by an Investigator or designee. If required, subjects will be transported to a hospital.  
During the Qualification and Treatment periods, the PI or designee will be on- site at the time of 
study drug administration until at least 6 hours postdose. Adv anced cardiac life support -certified 
staff will be present on site and an Investigator will be readily available by telephone.  
When not available on -site, the PI or designee will be on- call until the end of the study. While 
confined in the CRU, subjects wi ll be supervised by staff nurses and/or paramedics. Dedicated 
nurses and/or paramedics will be available to monitor AEs and perform safety measures. The date and time of rescue medication administration as well as the name and dosage regimen of the rescue medication will be recorded.  
6.2. Pharmacokinetic Assessments  
6.2.1. Pharmacokinetic Blood Sampling  
The complete blood sampling schedule for morphine and its metabolites is presented in  
Table  6-14. The complete blood sampling schedule for AZD4041 is presented in Table 6 -15. 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 58 of 95 Table  6-14 Pharmacokinetic Blood Sampling Schedule  for Morphine and its 
Metabolites  
Pharmacokinetic Blood Sampling - Scheduled Timepointsa 
Day 1: predose, 5, 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose  
Day 15: predose, 5, 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours postdose  
a Predose is relative to the start of morphine intravenous infusion. Nominal times listed are relative to the end of 
morphine  intravenous infusion. 
Table 6-15 Pharmacokinetic Blood Sampling Schedule for AZD4041  
Pharmacokinetic Blood Sampling - Scheduled Timepointsa 
Days 2 to 7: predose  
Day 8: predose, 5, 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose  
Days 9 to 14: predose  
Day 15: predose, 5, 15, 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours  postdose  
a. Nominal times listed are relative to the time of AZD4041  administration.  
Blood samples will be collected by direct venipuncture into a labeled tube containing the 
appropriate anticoagulant as specified by the bioanalytical facility. As an option to the subject  or 
if judged necessary by the clinical staff, blood samples may be collected from an indwelling cannula which will be placed in the vein of the subject.  
The actual time of all PK blood draws will be recorded and reported for all subjects.  
Windows for timed PK blood sample collections are presented in Table 6 -16. PK samples 
collected outside of the pre -specified windows will be documented as protocol deviations. Since 
actual times are to be used for the PK analysis, deviations will be reflected in the analysis unless indicated otherwise upon review of the data. 
Table 6-16 Acceptable Windows for Timed PK Blood Specimen Collection 
Procedures  
Elapsed Time  Accepted Window 
Predose within 5 minutesa 
> 0 hour to ≤ 30 minutes  ± 1 minute  
> 30 minutes to ≤ 4 hours  ± 2 minutes  
> 4 hours to ≤ 12 hours  ± 5 minutes  
> 12 hours to ≤ 24 hours  ± 10 minutes  
> 24 hours to 72 hours  ± 2 hours  
a. On Day 1 and Day 2, the accepted window can be increased to within 60 minutes.  
AZD4041, morphine, morphine-6-glucuronide, and morphine-3-glucuronide concentrations for 
PK assessments will be obtained through bioanalysis of the plasma derived from the blood samples drawn during this study, using validated bioanalytical methods.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 59 of 95 6.2.2. Pharmacokinetic Urine Sampling  
The complete urine sampling schedules are presented in Table 6 -17 for AZD4041. 
Table 6-17 Pharmacokinetic Urine Sampling Schedule for AZD4041  
Pharmacokinetic Urine Sampling  - Scheduled Timepointsa 
Day 15  Predose spot collection, 0-6 hours, 6 -12 hours, 12 -24 hours, 24-48 hours , and 
48-72 hours postdose  
a. Urine will be collected at the specified intervals  (-60 minutes for predose spot collection a nd ±20 minutes  for 
postdose spot collections ) 
AZD4041 concentrations for PK assessments will be obtained through bioanalysis of the urine 
collected during this study, using a validated bioanalytical method.  
6.2.3. Pharmacokinetic Sample Processing, Storage and Shipping  
Blood and urine samples for PK determination will be processed, stored, and shipped according 
to the sample processing instructions supplied by the bioanalytical facility.  
7. ADVERSE EVENTS DOCUMENTATION  
7.1. Definitions  
An AE  is defined as any untoward medical occurrence in a subject administered an IP and which 
does not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and unintended sign (including a clinically significant abnormal clinical la boratory 
finding, for example), symptom, or disease temporally associated with the use of an IP, whether 
or not related to the IP . 
A suspected adverse reaction (SAR) is any AE for which there is a reasonable possibility the drug caused the AE. ‘Reasonable possibility’ means there is evidence to suggest a causal 
relationship between the drug and the AE . A suspected adverse reaction implies a lesser degree 
of certainty about causa lity than adverse reaction, which means any AE caused by a drug. 
An AE  may be: 
• A new illness,  
• Worsening of a concomitant illness,  
• An effect of the study drug  including comparator; it could be an abnormal clinical 
laboratory value as well as a significant shift from baseline within normal range which an  
Investigator considers to be clinically important.  
Surgical procedures themselves are not AEs. They are therapeutic measures for conditions that 
required surgery. The condition for which the surgery is requir ed is an AE, if it occurs or is 
detected during the study period. Planned surgical measures permitted by the clinical study protocol and the conditions(s) leading to these measures are not AEs , if the condition(s) was 
(were) known before the start of study  treatment. In the latter case, the condition should be 
reported as medical history. 
A SAE or reaction is any untoward medical occurrence that at any dose: 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 60 of 95 • Results in death,  
• Is life -threatening, 
• Requires inpatient hospitalization or prolongation of existin g hospitalization, 
• Results in persistent or significant disability or incapacity (defined as a substantial 
disruption of a person’s ability to conduct normal life functions),  
• Is a congenital anomaly or birth defect, 
• Is an important medical event (including  development of drug dependence or drug abuse) 
that may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above (according to medical judgment of an  Investigator) 
An AE  of special interest (AESI: serious or non -serious) is one of scientific and medical concern 
specific to the Sponsor’s drug product, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor may be appropriate. An AESI is a noteworthy event for the particular product or class of products that a Sponsor may want to monitor carefully. It could be serious or non-serious (eg, hair loss, loss of taste, impotence), and could include events that might be potential precursors or prodromes for more serious medical conditions in susceptible individuals. Such events may require further investigation in order to characterize and understand it. Depending on the nature of the event, rapid communication by the Sponsor to other parties (eg, reg ulatory authorities) might also be warranted. 
The following AESI(s) has been specified for the study intervention(s) in this protocol:  
• Cardiac arrhythmia (including NSVT ) 
Non-serious AESIs are to be recorded in electronic data capture ( EDC) within 72 hours, and 
serious AESIs are to be reported to the sponsor within 24 hours. 
7.2. Severity Assessment  
All AEs will be graded per the current National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (NCI -CTCAE).  
Every effort will be made to obtain an  adequate evaluation of the severity.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 61 of 95 7.3. Causality Assessment  
An Investigator will determine the relationship of any AE  to the study drug using the guidelines 
presented  in Table 7 -1. 
Table 7-1 Adverse Event Relationship to Study Drug  
Relationship to Drug  Comment  
Reasonable Possibility  A temporal relationship exists between the AE onset and 
administration of the IP that cannot be readily explained by the 
subject’s clinical state or concomitant therapies.  
Furthermore, the AE appears with some degree of certainty to be 
related, based on th e known therapeutic and pharmacologic actions or 
AE profile of the IP. 
In case of cessation or reduction of the dose the AE may abate or 
resolve and it may reappear upon rechallenge.  
No Reasonable Possibility  Evidence exists that the AE has an etiology other than the IP. 
For SAEs, an alternative causality must be provided ( eg, preexisting 
condition, underlying disease, intercurrent illness, or concomitant 
medication).  
AE = adverse event; IP = investigational p roduct; SAE = serious adverse event  
7.4. Adverse Event Monitoring  
For the purposes of this study, the monitoring period for AEs extends from the pre- trial 
evaluation until the follow -up visit. Registration of new AEs will start from the moment of ICF 
signature and will stop 7 days after the last study drug administration (ie, stop registration on 
new AEs on follow-up visit in case last AZD4041 dose was administered on Day 15).  
Subjects will be questioned on their health status from the beginning of the study, before departure from the clinical site, and at the follow-up visit. Open-ended questions will be asked. 
During the study, all AEs reported by the subject, observed by the clinical staff, or elicited by 
general questioning will be recorded for all subjects and reported in the CRF.  
From the signing of the ICF until the first study drug administration, AEs will be recorded as 
screening events or as part of on the medical history eCRF page, as applicable. AEs occurring after study drug administration will be recorded on AE eCRF page and indicated as TEAEs in the Clinical Study Report, as well as non -serious AESI  (defined in Section  7.1). 
Any AE which remains unresolved as of the last study visit will require an evaluation and 
follow -up until the AE has been resolved, stabilized or a reasonable explanation for its 
persistence found, or is deemed mild and safely resolving. 
In the case of AEs deemed related to the IP, every effort will  be made to determine the final 
outcome. 
If necessary, every effort will be made to obtain an adequate follow-up of the subjects. Should 
any subject choose to withdraw from the study, they will be advised of the safety precautions to be taken. For those subjects whose status is unclear because they fail to appear for study visits 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 64 of 95 8.1.3. Completer Population  
The Completer Population will include all subjects in the Safety Population who complete the 
entire T reatment phase and the follow-up period (up to at least Day 22). This population will be 
used for inferential analysis of maximum postdose increase in E tCO 2 (Emax (postdose – predose) ), 
maximum postdose reduction in SpO 2 (Emax (predose – postdose) ), and maximum pos tdose decrease in 
respiratory rate  (Emax (predose – postdose) ). 
8.1.4. Pharmacokinetic Population  
All subjects in the Safety Population who receive at least 1 dose of morphine  or AZD4041 and 
have at least 1 PK concentration after dosing will be included in the PK Population. 
The PK population will be further described in a SAP. 8.2. Demographic Data and Other Baseline Characteristics  
Listings and descriptive summary statistics of demographic  (age, height, weight and BMI)  and 
baseline data will be presented.  
Statistics for demographic and baseline data will be detailed in a Statistical Analysis Plan  (SAP) . 
8.3. Safety  
Statistics for summary of AEs and safety results will be detailed in a SAP.  
8.3.1. Safety Endpoints  
The primary safety endpoint s are:  
• Incidence of increased E tCO
2 of at least 10 mmHg compared to baseline or >50 mmHg 
(sustained for at least 30 seconds)  
• Incidence of reduction in SpO 2 to <92% (sustained for at least 30 seconds) 
The secondary safety endpoints are: 
• Mean time to reduction in SpO 2 to <92% (sustained for at least 30 seconds) 
• Mean duration of reduction in SpO 2 to <92% (sustained for at least 30 seconds) 
• Maximum postdose reduction of SpO 2 adjusted for baseline  
• Mean postdose SpO 2 
• Mean time to each increased E tCO 2 episode of at least 10 mmHg compared to baseline or 
>50 mmHg (sustained for at least 30 seconds) 
• Mean duration of each increased E tCO 2 episode of at least 10 mmHg compared to 
baseline or >50 mmHg (sustained for at least 30 seconds) 
• Maximum postdose increase in E tCO 2 adjusted for baseline  
• Mean postdose E tCO 2 
• Incidence of reduced respiratory rate to <6 breaths/min (sustained for at least 30 seconds)  
• Mean time to each reduced respiratory rate episode of <6 breaths/min (sustained for at 
least 30 seconds)  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 65 of 95 • Mean duration of each reduced respiratory rate episode of <6 breaths/min (sustained for 
at least 30 seconds)  
• Maximum postdose decrease in respiratory rate adjusted for baseline  
• Mean postdose respiratory rate  
• Incidence, frequency, severity and relationship of AEs 
• Vital signs measurements ( BP, HR, and oral temperature)  
• ECGs  (12-lead safety ECGs, 12-lead dECGs, and ECG telemetry) 
• Clinical laboratory test results (clinical chemistry, hematology, coagulation, urinalysis) 
• Physical examination findings  
• Type of medical intervention used, summarized for each event of significantly increased 
EtCO 2, reduced SpO 2 or respiratory rate  
8.3.2. Safety Analysis 
 Respiratory Depression  Analysis  
Summary statistics and inferential analysis for respiratory depression endpoints will be done 
using the Completer Population. 
Incidence of increased E tCO 2 of at least >50 mmHg will be summarized by treatment and time 
point using frequency tables. Mean time to each increased E tCO 2 episode of at least >50 mmHg, 
mean duration of each increased E tCO 2 episode of at least >50 mmHg, and mean postdose 
EtCO 2 will be summarized by treatment and time point using descriptive statistics. Maximum 
postdose increase in E tCO 2 Emax (postdose – predose)  will be summarized by treatment using 
descriptive statistics and inferential analysis. E tCO 2 averages (predose averag e from Days 2 to 
15), and postdose average on Day 15 will also be summarized by treatment using descriptive 
statistics and inferential analysis. For each event of significantly increased ETCO 2, type of 
medical intervention used will be listed.  
Incidence of  reduction in SpO 2 to <92% will be summarized by treatment and time point using 
frequency tables. Mean time to reduction in SpO 2 to <92%, mean duration of reduction in SpO 2 
to <92%, and mean postdose SpO 2 will be summarized by treatment and time point usin g 
descriptive statistics. Maximum postdose reduction of SpO 2 Emax (predose – postdose)  will be 
summarized by treatment using descriptive statistics and inferential analysis. SpO 2 averages 
(predose average from Days 2 to 15), and postdose average on Day 15 will also be summarized by treatment using descriptive statistics and inferential analysis. For each event of significantly reduced SpO
2, type of medical intervention used will be listed.  
Incidence of reduced respiratory rate to <6 breaths/min will be summ arized by treatment and 
time point using frequency tables. Mean time to each reduced respiratory rate episode of < 6 breaths/min, mean duration of each reduced respiratory rate episode of <6 breaths/min, and mean postdose respiratory rate will be summarize d by treatment and time point using descriptive 
statistics. Maximum postdose decrease in respiratory rate
 Emax (predose – postdose) will be summarized 
by treatment using descriptive statistics and inferential analysis. Respiratory rate averages 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 66 of 95 (predose av erage from Days 2 to 15), and postdose average on Day 15 will also be summarized 
by treatment using descriptive statistics and inferential analysis.  
For Et CO 2, SpO 2, and respiratory rate the following figures will be generated:  
1) Mean (± SD) treatment by tim e point for Day 1 Morphine alone matched to Day 15 
Morphine + AZD4041  
2) Mean (± SD) treatment by time point for Day 1 Morphine alone matched to Day 15 
Morphine + Placebo  
3) Mean (± SD) treatment by time point for Days 2-15 predose AZD4041 vs. Days 2-15 
predose Placebo  
4)  Boxplot for E max Day 1 Morphine alone matched to Day 15 Morphine + AZD4041 
5) Boxplot for E max Day 1 Morphine alone matched to Day 15 Morphine + Placebo  
6) Boxplot for E max Day 15 Morphine + AZD4041 vs. Day 15 Morphine + Placebo  
For all inferential analysis on E tCO 2, SpO 2, and respiratory rate, mixed- effects models will be 
used for E max and averaged measures. The models will include treatment as a fixed effect, and 
baseline as a covariate. Homogeneit y of treatment variances will be explored to determine if 
subject may be considered a random effect. 
For maximum postdose increase in Et CO 2 (Emax (postdose – predose) ), maximum postdose reduction in 
SpO 2 (Emax (predose – postdose) ), and maximum postdose de crease in respiratory rate  (Emax (predose – 
postdose) ), the following contrasts will be explored in the mixed -effects models:  
1) E: Morphine + AZD4041 (Day 15) vs A: Morphine alone (Day 1)  
2) F: Morphine + Placebo (Day 15) vs B: Morphine alone (Day 1)  
3) E: Morphine + AZD4041 (Day 15) vs F: Morphine + Placebo (Day 15)  
For Et CO 2, SpO 2, and respiratory rate averages (predose average from Days 2 to 15), and 
postdose average on Day 15, the following contrasts will be explored in the mixed- effects 
models: 
1) E (postdose): Morphine + AZD4041 (postdose average Day 15) vs C + E (predose): 
AZD40401 (predose average Days 2-15)  
2) C + E (predose): Morphine + AZD4041 (predose average Days 2 -15) vs D + F (predose): 
Morphine + Placebo (predose average Days 2 -15) 
 12-lead dig ital ECG Statistical Methodology  
From  the dECG data, the following parameters will be derived:  
1) QTcF will be calculated as QTcF = QT*RR -1/3, where the QT interval is in milliseconds 
and the RR interval is in seconds.  
2) Heart rate will be calculated, based on the RR interval as HR = 60/RR interval, where the RR interval is in seconds.  
3) Calculation  of derived parameters will be performed after smoothing of QT and RR data.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 67 of 95 The dECG data will be smoothed on an individual basis before performing the derivations above 
and prior to calculation of any changes from baseline or descriptive statistics. For each subject it will be done as follows: the mean value of all the measurements will be taken provided that at least 4 measurements are present and the time between the first and last is greater than 2.75 minutes or else, the smoothed value at the corresponding target time point will be set to missing.  
Digital ECG results will be listed by treatment ( Morphine and AZD4041 vs Morphine and 
placebo) for each subject and time point and will include all individual and smoothed values of PR, RR, QRS, QT interval, and the derived values of QTcF and HR. All smoothed and derived parameters will have changes from baseline derived and present ed.  
Descriptive statistics will be presented by treatment and time point for smoothed values and changes from baseline of smoothed values of PR, RR, QRS, QT; derived values and changes from baseline for QTcF and HR will also be included. The baseline for the dECG measurements will be the (smoothed) predose assessment on Day 1.   
Outliers with respect to PR, QRS, HR, RR and QTcF will also be tabulated for the following 
categories : 
For QTcF:  
• Absolute value > 450 ms and ≤ 480 ms  
• Absolute value > 480 ms and ≤ 500 ms  
• Absolute value > 500 ms  
• Increase from baseline > 30 ms and ≤ 60 ms  
• Increase from baseline > 60 ms   
The maximum postdose values for PR interval will be summarized by treatment according to the following categories:   
• ≤220 ms  
• >220 and ≤ 240 ms (all instances flagged in the listing*)  
• >240 ms (all instances flagged in the listing **)  
The maximum postdose values for QRS duration will be summarized by treatment according to the following categories:   
• ≤115 ms   
• >115 ≤ 119 ms (all instances flagged in the listing*)  
• >119 ms (all instances flagged in the listing**)  
The maximum/min postdose values for HR will be summarized by treatment according to the following categories:   
• <40 bpm (all instances flagged in the listing**)   
• 40 - <50 bpm (all instances flagged in the listing*)  
• ≥50 bpm and ≤100 bpm  
• >100 - ≤120 bpm (all instances flagged in the listing*)   
• >120 bpm (all instances flagged in the listing**)   
The maximum/min postdose values for RR will be summarized by treatment according to the following categories:   
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 68 of 95 • <500 ms (all instances flagged in the listing* *) 
• 500 ms - < 600 ms (all instances flagged in the listing*)  
• ≥ 600 ms ≤ 1200 ms  
• > 1200 ms ≤ 1500 ms  (all instances flagged in the listing*)   
• >1500 ms (all instances flagged in the listing**) 
All calculations of dECG parameters and reporting descr ibed in this section will be performed by 
AltaSciences.  
 All Other Safety Analysis  
Summary statistics for all other safety analysis will be done using the Safety Population. 
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and 
characterized as pre- treatment and treatment -emergent according to the intake of the study drugs. 
The occurrence and incidence of TEAEs will be summarized by MedDRA s ystem organ class 
and preferred term and by treatment. The occurrence and incidence of TEAEs will also be summarized by severity and by relationship to the study drugs. Adverse events leading to discontinuation and SAEs  will be listed.  
Clinical laboratory parameters will be summarized by visit using descriptive statistics. Values within and outside the reference range will also be summarized using frequency tablets. Vital sign and ECG parameters and change from baseline (predose) will be summarized at each time point by treatment using descriptive statistics. Physical examination abnormalities and C -SSRS 
findings will be listed.  
8.4. Pharmacokinetics  
The PK analysis will be carried out according to AZ SOPs. P harmacokinetic  data handling and 
analysis will be furth er detailed in a SAP.  
8.4.1. Pharmacokinetic Parameters  
The PK parameters will be determined by non -compartmental analysis using appropriate 
software. The PK parameters for AZD4041, morphine, morphine-6- glucuronide and morphine -3-
glucuronide are presented in Table 8 -1. 
Table 8-1 Pharmacokinetic Parameters in Plasma  
Parametera Definition 
For morphine, morphine-6-glucuronide and morphine -3-glucuronide (Day 1 and 15)  
Cmax Maximum observed concentration occurring at time tmax 
tmax Time of maximum observed concentration. If the maximum observed 
concentration is not unique, then the first maximum is used 
AUC 0-t Area under the concentration time curve from the time of last dosing to the 
time of last quantifiable concentration (T last)  
AUC 0-∞  Area under the concentration time curve extrapolated to infinity, calculated as 
AUC 0-T + C last/λZ, where C last is the last quantifiable concentration at time T last 
t1/2,z  Terminal elimination half -life, calculated as ln(2)/λ 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 69 of 95 Parametera Definition 
Tlast Time of last measurable observed concentration  
CL Total body clearance, calculated as Dose/AUC 0-∞ (parent drug only)  
Vz Volume of distribution based on terminal phase (parent drug only)  
For AZD4041 
Days 2 to 7 and Days 9 to 14:  
Ctrough  Predose concentration observed immediately prior to the next successive dose  
Days 8 and 15 
Cmax,ss maximum observed plasma concentration  
tmax,ss time to maximum observed plasma concentration 
Ctrough Predose concentration observed immediately prior to the next successive dose  
AUC τ area under the concentration time curve over the dosing interval at steady-
state, calculated from 0 to 24 hours (dosing interval)  
Cav average concentration during a dosing interval, after the last dose of a multiple dose regimen, calculated as AUCτ/τ  
t1/2,z  Terminal elimination half -life, calculated as ln(2)/λ z (Day 15 only)  
CLss/F  Apparent total body clearance  at steady -state, calculated as Dose/ AUC τ 
Vzss/F Apparent volume of distribution  at steady -state, based on terminal phase   
a. A complete list of PK parameters that will be used for PK calculation and presented in the PK listings will be 
included in the SAP.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 75 of 95 Society of Actuaries, 2019 
Opioid Epidemic Cost the U.S. Economy at Least $631 Billion Over Four Years: Society of 
Actuaries’ Analysis. Society of Actuaries https://www.soa.org/resources/announcements/press-releases/2019/opioid-epidemic- cost-631- billion/ (2019). 
Stoops et al, 2010 
Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL. Intravenous oxycodone, 
hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. 
Thannickal et al, 2018 
Thannickal TC et al. Opiates increase the number of hypocretin-producing cells in human and 
mouse brain and reverse catalepsy in a mouse model of narcolepsy. Science Translational Medicine 10, doi:10.1126/scitranslmed.aao4953 (2018) 
Thompson et al. 1999 
Thompson PI, Joel SP, John L, Wedzicha JA, Maclean M, Slevin ML. Respiratory depression 
following morphine and morphine -6-glucuronide in normal subjects. Br J Clin Pharmacol. 1995 
Aug;40(2):145-52.  
Verbekt  et al,  2017 
Verberkt CA, van den Beuken- van MH, Schols JM, Datla S, Dirksen CD, Johnson MJ, van 
Kuijk SM, Wouters EF, Janssen DJ. Respiratory adverse effects of opioids for breathlessness: a 
systematic review and meta-analysis. European Respiratory Journal. 2017 Nov 1;50(5). 
Viscusi  et al , 2021 
Viscusi ER, Torjman MC, Munera CL, Stauffer JW, Setnik BS, Bagal SN. Effect of 
difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double‐blind, placebo‐controlled trial. Clinical and Translational Science. 2021 Sep;14(5):1886-93. 
Waugh et al, 2011 
Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events 
during procedural sedation: a meta-analysis. J Clin Anesth 2011;23(3):189-196. 
Wakeman et al, 2020 
Wakeman, S. E. et al. Comparative Effectiveness of Different Treatment Pathways for Opioid 
Use Disorder. JAMA network open 3, e1920622, doi:10.1001/jamanetworkopen.2019.20622 (2020). 
Webster et al, 2011 
Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on 
intravenous morphine -induced high, drug liking, and euphoric effects in experienced, 
nondependent male opioid users. Drugs R D. 2011 Sep 1;11(3):259-75. 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 77 of 95 10. APPENDIX 1: ETHICS  
10.1. Institutional Review Board  
This protocol and the ICF will be submitted to an IRB  (or Independent Ethics Committee[ IEC]) 
prior to initiation of the study and the study will not start until the Board has approved the 
documents. Notification of the Board’s approval will be appended to the f inal report.  
10.2. Ethical Conduct of the Study  
This study will be conducted in compliance with the study protocol, the ethical principles that have their origins in the Declaration of Helsinki, the International Council for Harmonisation  
(ICH) Guideline E6 for Good Clinical Practice (GCP), the FDA GCP Code of Federal Regulations (CFR) Title 21 (part 56), the EU Clinical Trial Directive (EC) No. 2001/20/EC, the European regulation EU 536/2014 and the Tri- Council Policy Statement (Canada).  
10.3. Subject  Information and Consent  
Before screening activities commence, each volunteer will be given a copy of the ICF  to read, as 
well as a full explanation of the purpose of the study, the procedures to be carried out, and the 
potential AE (s). Once this essential  information is provided to the volunteer and the physician in 
charge or delegate has the conviction the volunteer understands the implications of participating 
in the study, and if the volunteer chooses to continue the screening  process , they will be 
requested to sign and date a properly executed ICF prior to enrollment. Subjects will be assured 
they may withdraw from the study at any time without jeopardizing their medical care or future study participation (for which they qualify).  
Subjects will be given a signed copy of the ICF. If an amended or revised ICF is introduced during the study, each subject’s further consent must b e obtained. 
10.4. Subject Confidentiality  
Investigators and the Sponsor will preserve the confidentiality of all subjects taking part in the study, in accordance with GCP and local regulations. Subjects should be identified by a unique subject identifier on all study documents provided to the Sponsor . In compliance with Federal 
regulations/ICH GCP Guidelines, it is required an  Investigator and institution permit authorized 
representatives of the company, of the regulatory agency(s), and IRB access to review the subject’s original medical records for verification of study -related procedures and data. An  
Investigator is obligated to inform the  subject that his/her study -related records will be reviewed 
by the above named representatives without violating the subject’s confidentiality.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 78 of 95 11. APPENDIX 2: DATA COLLECTION, RETENTION, AND MONITORING  
11.1. Case Report Forms  
The subject level data is entered by the site from the source document into a study specific 
21 CFR Part 11 compliant electronic clinical database to accurately collect data for each subject included in a clinical trial. Screen failure data may be entered into the database at the discretion of the Sponsor, when included in the contracted scope of work. 
11.2. Data Management and Processing  
Data management develops documentation to define activities performed during the data 
management conduct of the study trial. The EDC system is the tool used to conduct all data management data cleaning activities for monitoring, data review and queries. Data management will use a combination of automated programmed edits and manual data review listings to issue queries for non- conforming or discrepant data. Data management activities are performed in 
accordance with the SOPs and study -specific data management documents.  
Database locking is guided by the Data Management Locking Checklist based on the concept 
that all site activitie s are complete, data are considered clean and without errors and CRF signoff 
by the Principal Investigator or delegate has been completed. User access is removed as part of 
the locking process.  
Data from the clinical database will be output as SAS
® dataset s. All data will be included with 
the final report provided to the Sponsor. 
11.3. Quality Control and Quality Assurance 
Designated personnel from the quality assurance ( QA) unit(s) of the clinical, PK and statistical 
facilities will be responsible for maintainin g QA systems to ensure that the trial is conducted and 
that clinical/PK/statistical data is generated, documented and reported in compliance with the 
protocol and the integrated addendum to ICH E6: Guideline for Good Clinical Practice E6 (R2). 
Designated p ersonnel from each corresponding operation unit (eg, clinical, PK, and statistical 
facilities) will be responsible to maintain and assure the QC of all data generated and 
documented in compliance with the protocol.  
All parts of the bioanalytical phase of the study and all its documentation will be subject to inspection by the QA unit of the bioanalytical facility to ensure that the data are generated, documented and reported in compliance with the protocol and applic able requirements as 
outlined in the FDA and Organization for Economic Co -Operation and Development ( OECD) 
Principles of GLP.  
11.4. Record Retention  
All essential documents and records will be maintained by the clinical site in accordance with, and for the perio d specified in the applicable regulatory requirement(s) (FDA CFR 312.57 [C] ). 
11.5. Monitoring of the Study  
The sponsor or its representative may monitor the study in order to maintain current and personal knowledge of the study through review of the records, comparison with source documents, observation and discussion of the conduct and progress of the study. The clinical site will permit trial- related monitoring, audits, institutional review board (IRB)/independent ethics committee 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 79 of 95 (IEC) review, and regulatory inspection(s) by providing direct and/or virtual access, where 
possible, to source data/documents.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 80 of 95 12. APPENDIX 3: ADMINISTRATIVE PROCEDURES  
12.1. Liabilities  
It is the Sponsor’s responsibility to guarantee sufficient insurance coverage should any serious 
events or deaths result , either directly or indirectly, from the execution of the present protocol. 
12.2. Adherence to Protocol  
Excluding an emergency situation in which proper treatment is required for the protection, safety 
and well-being of the study subjects, the study will be conducted as described in the approved protocol and performed according to ICH/GCP and the applicable regulatory requirements. Any deviation from the protocol will be recorded and explained. 
If amendments to the protocol and/or amendments or revisions to the ICF are required, the 
modifications will be documented and submitted to an IRB for approval.  
12.3. COVID-19 Response Plan  
Regulatory authorities have recognized that the Coronavirus Disease 2019 (COVID-19) pandemic may impact the conduct of clinical trials of medical products. Challenges may arise, 
for example, from quarantines, site closures, travel limitations, interruptions to the supply chain 
for the IP(s), or other considerations if site personnel or study participants become infected with COVID-19. These challenges may lead to difficulties in meeting protocol- specified procedures, 
including administering or using the IP or adhering to protocol- mandated visits and 
laboratory/diagnostic testing. To accommodate these challenges and mitigate safety risks associated with COVID -19, protocol modifications may be required which include (and are not 
limited to):  
• Conducting the study in multiple (smaller) subject groups;  
• Altering the timing of study procedures and subject confinement; 
• Modification of standard inclusion or exclusion criteria;  
The exact mitigations will be documented in the study Risk Assessment and Mitigation Plan.  
Additional health checks including COVID-19 testing, body temperature monitoring, etc. may be performed during the trial, even if not planned within the protocol. 
12.4. Statement of Investigator  
The form “Qualified Investigator Undertaking” will be signed by an  Investigator responsible for 
the medical decisions and care provided to the subjects (being also referred to as the “qualified 
investigator”) prior to the commencement of his responsibilities with respect to the clinical trial, as required by the Food and Drug Regulations. The undertaking form will be maintained with the trial records and will be made available up on request. 
The FDA 1572 form, Statement of Investigator [Title 21, CFR Part 312], will be signed by the Investigator, and will be kept on file. 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 81 of 95 12.5. Delegation of Investigator Duties  
An Investigator will ensure all personnel involved in the trial are adequately qualified and 
informed about the protocol, any amendments to the protocol, the study treatments, and their 
trial- related duties and functions.  
An Investigator will maintain a list of sub -inves tigator(s) and other appropriately -qualified 
persons to whom he /she delegates significant trial -related duties.  
Should an  Investigator delegate the supervision of the IP  administration to a designated person, 
this individual must have the appropriate profe ssional -legal qualifications  and certifications . An 
Investigator should also ensure key staff personnel have the appropriate medical qualifications to effectively conduct or supervise any potential resuscitation procedures. 
12.6. Premature Termination or Suspens ion of a Study  
The Sponsor or its representative may terminate the study at any time for scientific or corporate 
reasons.  
If the trial is prematurely terminated or suspended for any reason, the clinical site or an  
Investigator (or delegate) should promptly inform the trial subjects, should assure appropriate 
therapy and follow -up for the subjects and should inform the regulatory authority(ies) when 
required. 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 82 of 95 13. APPENDIX 4: PROTOCOL  REVIEW AND APPROVALS 
 
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 83 of 95 TITLE: A RANDOMIZED, DOUBLE -BLIND, PLACEBO- CONTROLLED, FIXED 
SEQUENCE STUDY TO ASSESS THE EFFECT ON RESPIRATORY DRIVE OF 
MULTIPLE DOSES OF AZD4041 WHEN CO- ADMINISTERED WITH A SINGLE DOSE OF 
MORPHINE IN HEALTHY RECREATIONAL OPIOID USERS  
 
 I have carefully read this study protocol and agree it contains all necessary information required 
to conduct this study. I agree to conduct the study according to this protocol and in accor dance 
with GCP  and the applicable regulatory requirements. 
___________________________ Principal Investigator Name (Please Print)  
___________________________ ____________________ 
Principal Investigator Signature  Date (yyyy/mm/dd) 
Altasciences Clinical Kansas Inc  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 85 of 95 14. APPENDIX 5: LIST OF ABBREVIATIONS  
AE Adverse Event  
AESI Adve rse Event of Special Interests  
ALT  Alanine Aminotransferase  
ALP  Alkaline Phosphatase  
AST  Aspartate Aminotransferase  
AV Atrioventricular   
BMI Body Mass Index  
BP Blood Pressure  
bpm Beats per Minute 
CFR Code of Federal Regulations  
CNS  Central Nervous System  
COVID-19 Coronavirus Disease 2019  
CRF Case Report Form  
CRU Clinical Research Unit  
CSF Cerebrospinal Fluid  
C-SSRS Columbia Suicide Severity Rating Scale  
CV Coefficient Of Variation  
CYP  Cytochrome P450  
dECG Digital Electrocardiogram  
DORA  Dual Orexin Receptor Antagonist  
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition  
ECG Electrocardiogram  
eCRF Electronic Case Report Form  
EClysis© User -Interactive, Modular Computer -Based System for dECG Data Processing, 
Analysis and Measurement of ECG Intervals and Wave Amplitudes, Exports and 
Reports, used by the AstraZeneca ECG Centre  
EDC  Electronic Data Capture 
EEG  Electroencephalogram  
EtCO 2 End Tidal Carbon Dioxide  
EU European Union  
FDA  Food and Drug Administration  
FSH Follicle Stimulating Hormone  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 86 of 95 HBsAG  Hepatitis B Surface Antigen  
HCl Hydrochloride  
HCVAb  Hepatitis C Virus  Antibody  
hERG Human Ether -A-Go -Go-Related Gene  
HIV Human Immunodeficiency Virus  
HR Heart Rate  
IC50 Half Maximal Inhibitory Concentration  
ICF Informed Consent Form  
ICH International Council for Harmonisation 
IEC Independent Ethics Committee  
IP Investigational Product  
IRB Institutional Review Board  
kg Kilogram  
L Litre  
LH Luteinizing Hormone  
MAD  Multiple Ascending Dose 
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
min Minute  
mL Millilitres  
mmHG  Millimetre of Mercury  
NCI-CTCAE  National Cancer Institute’s Common Terminology Criteria for Adverse Events  
ng Nanograms  
NIDA  National Institutes on Drug Abuse  
NOAEL  No-Observed -Adverse-Effect Level  
NSVT  Non-Sustained Ventricular Tachycardia  
OECD  Organization for Economic Co-Operation and Development 
OTC  Over -The -Counter  
OUD  Opioid Use Disorder  
OX1/2  Orexin Receptor 
PK Pharmacokinetic  
PR (PQ)  ECG interval measured from the onset of the P wave to the onset of the 
QRS complex  
PT Preferred Term  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 87 of 95 QA Quality Assurance  
QRS  ECG Interval Measured from the onset of QRS Complex to the J -Point  
QT QT Interval is the time from the start of the Q Wave to the end of the T Wave, 
Time Taken for Ventricular Depolarization and Repolarization  
QTC  Qt Interval Corrected for Heart Rate  
QTcF  Qt Interval Corrected for Heart Rate Using Fridericia's Correction Formula  
RR Time Elapsed Between Two Successive R -Waves of the QRS Signal on the ECG  
SAD  Single Ascending Dose 
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAR  Suspected Adverse Reaction  
SD Standard Deviation  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SMP Safety Management Plan  
ST ST Segment of the ECG  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T T Wave of the ECG  
TEAE  Treatment -Emergent Adverse Event  
THC  Tetrahydrocannabinol  
ULN  Upper Limit of Normal  
VPC  Ventricular Premature Contractions  
WHO -DDE  World Health Organization Drug Dictionary Enhanced  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 88 of 95 15. APPENDIX 6: CLINICAL LABORATORY EVALUATIONS  
Laboratory Test  Panel  Description  
General biochemistry:  Alanine aminotransferase, aspartate aminotransferase , albumin, alkaline phosphatase, bilirubin total, 
chloride, creatinine  (including eGFR using the MDRD equation) , glucose,  potassium, sodium , BUN, 
magnesium, calcium  
Endocrinologya FSH 
Hematology:  White cell count with differential (absolute values of neutrophil, lymphocyte, monocyte, eosinophil, and 
basophil), red cell count, hemoglobin, hematocrit, mean corpusc ular volume , and platelet count  
Coagulation tests:  Activated partial thromboplastin time, prothrombin time , INR  
Serologya: HIV Ag/Ab Combo, Hepatitis B surface antigen and Hepatitis C virus ,  
Urinalysis: Color, clarity, specific gravity, pH, leukocyte, protein, glucose, ketones, bilirubin, blood, nitrite, 
urobilinogen. Microscopic examination will only be performed if the dipstick test is outside of the 
reference range for leukocyte, blood, nitrite or protein  
Urine drug screen:  Amphetamines, barbiturates, cannabinoids, cocaine, o piates , benzodiazepines , ethanol, and 
phencyclidine  
Pregnancy test:  Serum pregnancy test  
Abbreviations: BUN = blood urea nitrogen; eGFR = estimated glomerular filtration rate; FSH = follicle stimulating hormone; INR = international normalization 
ratio; MDRD = Modification of Diet in Renal Disease  
 
 
a Screening visit only.  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 89 of 95 16. APPENDIX 7: COLUMBIA- SUICIDE SEVERITY RATING SCALE (C- SSRS)  – 
BASELINE/SCREENING  VERSION 
The Columbia- Suicide Severity Rating Scale Baseline/Screening Version will be provided to the 
clinical site and is not included here in its entirety.  
 

Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 90 of 95 17. APPENDIX 8: COLUMBIA- SUICIDE SEVERITY RATING SCALE (C- SSRS) – 
SINCE LAST VISIT VERSION  
The Columbia- Suicide Severity Rating Scale Since Last Visit Version will be provided to the 
clinical site and is not included here in its entirety.  
 

Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 91 of 95 18. APPENDIX 9: CLINICAL OPIOID WITHDRAWAL SCALE (COWS)  
 

Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 92 of 95  
 

Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 93 of 95 19. APPENDIX 10: CONTRACEPTION GUIDANCE  
Non-sterilised males who are sexually active with a female partner of childbearing potential must 
use a condom for the duration of the treatment period and for no less than 120 days following the 
last administration of study drug. As a male condom is not considered to constitute a highly  
effective contraception method, it is recommended that female partners of a male study subject also use a highly effective method of contraception throughout the study and  the 
protocol- specified follow -up period. A highly effective method of contraception is defined as 
one that results in a low failure rate (ie, less than 1% per year) when used consistently and 
correctly. The acceptable methods of contraception are described in  the table below.  
 Table 1 Highly effective methods of contraception  
Barrier methods Hormonal methods  
Intrauterine device  
Intrauterine hormone -releasing system (UIS)a 
Bilateral tubal occlusion  
Vasectom yb 
Sexual abstinencec Combined (oestrogen and progestogen containing 
hormonal contraception) 
• Oral (combined pill)  
• Injectable  
• Transdermal (patch) 
Progestogen- only hormonal contraception 
associated with inhibition of ovulationd 
• Injectable  
• Implantable  
• Intravaginal  
a This is also considered a hormonal method.  
b With appropriate evidence of post -vasectomy surgical success.  
c Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of the study and if it is the preferred and usual life style of the subject.  
d Progestogen -only hormonal contraception, where inhibition of ovulation is not the primary mode of action (eg, 
minipill), is not accepted as a highly effective method).  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 94 of 95 20. APPENDIX 11: PHYSICAL EXAMINATION FORM  
Protocol No: D7460C00003   
Altasciences Project No : AZN- P1-265 
 
Version 2.0  (Amendment 01) , 16-SEP-2022  Page 95 of 95 21. APPENDIX 12: NEUROLOGICAL EXAMINATION FORM  
 